<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Stripes × Isomorphic Labs</title>
<link href="https://fonts.googleapis.com/css2?family=Roboto:wght@100;300;400;500;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
/* ══ CUSTOM FONTS ══ */
@font-face{font-family:"Lutz Stripes Web";src:url("Fonts/LutzStripesWeb-Regular.woff2") format("woff2"),url("Fonts/LutzStripesWeb-Regular.woff") format("woff");font-display:swap}
@font-face{font-family:'Graphik Web';src:url('Fonts/Graphik-Bold-Web.woff2') format('woff2'),url('Fonts/Graphik-Bold-Web.woff') format('woff');font-weight:700;font-style:normal;font-display:swap}

*,*::before,*::after{margin:0;padding:0;box-sizing:border-box}
:root{
--bg:#F6F6F6;--bg2:#F0F0F0;--bg3:#F2F2F2;--bg4:#EAEAEA;
--text:#212121;--text2:#555555;--text3:#999999;
--accent:#635BFF;--accent2:#80E9FF;--green:#24D164;--pink:#FF5CAA;--orange:#FF7A00;--red:#FF4D6D;
--border:#dddedb;
--font-d:'Lutz Stripes Web','Roboto',sans-serif;
--font-b:'Roboto',system-ui,sans-serif;
--font-m:'JetBrains Mono',monospace;
--font-l:'Lutz Stripes Web','Roboto',system-ui,sans-serif;
--font-g:'Roboto',system-ui,sans-serif;
}
html{scrollbar-width:thin;scrollbar-color:#ccc transparent}
body{font-family:var(--font-b);background:var(--bg);color:var(--text);overflow:hidden;-webkit-font-smoothing:antialiased;height:100vh}
::selection{background:var(--accent);color:#fff}
::-webkit-scrollbar{width:5px}::-webkit-scrollbar-track{background:transparent}::-webkit-scrollbar-thumb{background:#ccc;border-radius:3px}

/* ══ LOADING SCREEN ══ */
#loader{position:fixed;inset:0;z-index:10000;background:var(--bg);display:flex;flex-direction:column;align-items:center;justify-content:center;transition:opacity 1s cubic-bezier(.22,1,.36,1),visibility 1s,transform 1s cubic-bezier(.22,1,.36,1)}
#loader.done{opacity:0;visibility:hidden;pointer-events:none;transform:translateY(-10px)}
.loader-helix{position:relative;width:120px;height:160px;margin-bottom:32px}
.helix-strand{position:absolute;width:100%;height:100%;animation:helixSpin 2.4s linear infinite}
.helix-strand:nth-child(2){animation-delay:-1.2s}
.helix-node{position:absolute;left:50%;width:14px;height:14px;border-radius:50%;opacity:0;animation:helixFold 1.6s ease-out forwards}
.helix-strand:nth-child(1) .helix-node{transform-origin:center}
.helix-strand:nth-child(2) .helix-node{transform-origin:center}
.helix-bridge{position:absolute;left:50%;height:2px;background:linear-gradient(90deg,rgba(33,33,33,.15),rgba(100,100,100,.15));border-radius:1px;opacity:0;animation:bridgeFade 1.6s ease-out forwards;transform-origin:left center}
@keyframes helixSpin{
  0%{transform:rotateY(0deg)}
  100%{transform:rotateY(360deg)}
}
@keyframes helixFold{
  0%{opacity:0;transform:translateX(-50%) scale(0)}
  50%{opacity:1;transform:translateX(-50%) scale(1.2)}
  100%{opacity:1;transform:translateX(-50%) scale(1)}
}
@keyframes bridgeFade{
  0%,40%{opacity:0;width:0}
  70%{opacity:.6;width:40px}
  100%{opacity:.4;width:40px}
}
.loader-text{font-family:var(--font-l);font-size:12px;color:var(--text3);letter-spacing:.15em;text-transform:uppercase}
.loader-bar{width:200px;height:2px;background:var(--bg3);border-radius:1px;margin-top:16px;overflow:hidden}
.loader-bar-fill{height:100%;background:linear-gradient(90deg,#bbb,#666);width:0;animation:barFill 2s ease-out forwards}
@keyframes barFill{to{width:100%}}

/* ══ VIDEO BACKGROUND ══ */
#scene-container{position:fixed;inset:0;z-index:1;overflow:hidden;background:linear-gradient(135deg,#eef6ef 0%,#eaf3f7 100%)}
#scene-container video{position:absolute;bottom:0;right:0;width:85vw;height:85vh;object-fit:contain;opacity:.9;transition:opacity .8s ease}
#scene-container.panel-open video{opacity:.5}
#video-overlay{position:absolute;inset:0;background:radial-gradient(ellipse at 80% 80%,transparent 40%,rgba(246,246,246,.4) 100%);transition:background .5s ease}
#scene-container.panel-open #video-overlay{background:radial-gradient(ellipse at 60% 70%,transparent 20%,rgba(246,246,246,.6) 100%)}

/* ══ BRANDING (inside nav card) ══ */
.brand-overlay{display:flex;align-items:center;gap:10px;font-size:13px;font-weight:300;letter-spacing:.02em;opacity:.7;transition:opacity .3s,transform .3s;padding:6px 10px 14px;margin-bottom:4px;border-bottom:1px solid var(--border);overflow:hidden;flex-shrink:0}
.brand-overlay:hover{opacity:1;transform:translateX(2px)}
.brand-overlay .iso-logo{flex-shrink:0}
.brand-overlay .x-mark{font-family:var(--font-m);font-size:12px;color:var(--text3)}
.iso-logo{display:inline-block;position:relative;vertical-align:middle}
.iso-logo svg.iso-frame{display:block;height:100%}
.iso-logo .iso-lottie{position:absolute;top:0;left:0;overflow:hidden}
.iso-logo .iso-lottie svg{display:block}

/* ══ BACK BUTTON ══ */
.back-btn{position:fixed;top:28px;left:400px;z-index:60;display:flex;align-items:center;gap:10px;background:#fff;border:1px solid var(--border);border-radius:12px;padding:10px 18px;cursor:pointer;color:var(--text);font-family:var(--font-m);font-size:11px;letter-spacing:.08em;text-transform:uppercase;opacity:0;visibility:hidden;transform:translateX(-20px);transition:all .4s cubic-bezier(.22,1,.36,1)}
.back-btn.visible{opacity:1;visibility:visible;transform:translateX(0)}
.back-btn:hover{background:#f8f8f8;border-color:#bbb}
.back-btn svg{width:16px;height:16px;stroke:var(--text);stroke-width:2;fill:none}

/* ══ CLUSTER NAV (right side in content view) ══ */
.cluster-nav{position:fixed;right:48px;top:50%;transform:translateY(-50%);z-index:60;display:flex;flex-direction:column;gap:8px;opacity:0;visibility:hidden;transition:all .4s .2s}
.cluster-nav.visible{opacity:1;visibility:visible}
.cluster-nav-dot{width:10px;height:10px;border-radius:50%;cursor:pointer;transition:all .3s;opacity:.4;border:2px solid transparent}
.cluster-nav-dot:hover{opacity:.7;transform:scale(1.3)}
.cluster-nav-dot.active{opacity:1;transform:scale(1.5);box-shadow:0 0 0 3px rgba(255,255,255,.9),0 0 8px rgba(0,0,0,.1)}
.cluster-nav-dot .cn-tip{position:absolute;right:calc(100% + 12px);top:50%;transform:translateY(-50%);font-family:var(--font-m);font-size:9px;color:var(--text2);white-space:nowrap;opacity:0;transition:opacity .2s;pointer-events:none;text-transform:uppercase;letter-spacing:.08em}
.cluster-nav-dot:hover .cn-tip{opacity:1}

/* ══ FOCUS STATES ══ */
.nav-item:focus-visible,.nav-section-title:focus-visible,.back-btn:focus-visible,.cluster-nav-dot:focus-visible,button:focus-visible{outline:2px solid var(--accent);outline-offset:2px;border-radius:8px}

/* ══ CONTENT PANEL SYSTEM (floating cards) ══ */
#content-panels{position:fixed;top:0;right:0;bottom:0;left:396px;z-index:50;pointer-events:none;padding:24px 32px 24px 0}
.content-panel{position:absolute;top:24px;right:32px;bottom:24px;left:0;overflow-y:auto;opacity:0;visibility:hidden;transform:translateX(40px);transition:opacity .5s cubic-bezier(.22,1,.36,1),transform .5s cubic-bezier(.22,1,.36,1),visibility .5s;background:#fff;border:1px solid var(--border);border-radius:20px;box-shadow:0 2px 8px rgba(0,0,0,.04);pointer-events:none;padding:0}
.content-panel.active{opacity:1;visibility:visible;transform:translateX(0);pointer-events:auto}
.panel-inner{max-width:960px;margin:0 auto;padding:60px 48px 80px}
.panel-color-bar{height:2px;width:100%;position:sticky;top:0;z-index:2;border-radius:20px 20px 0 0;box-shadow:none;opacity:.5}
.panel-breadcrumb{font-family:var(--font-m);font-size:10px;color:var(--text3);letter-spacing:.1em;text-transform:uppercase;margin-bottom:32px;display:flex;align-items:center;gap:8px}
.panel-breadcrumb .bc-sep{color:var(--text3);font-size:8px}

/* ══ TYPOGRAPHY ══ */
.label{font-family:var(--font-b);font-size:11px;font-weight:500;text-transform:uppercase;letter-spacing:.15em;color:var(--text3);margin-bottom:12px;display:flex;align-items:center;gap:8px}
.label::before{content:'';width:20px;height:1px;background:var(--text3)}
h2.sec-title{font-family:var(--font-b);font-size:clamp(32px,4vw,52px);line-height:1.1;letter-spacing:-.03em;margin-bottom:16px;font-weight:300}
.sec-sub{font-size:17px;color:var(--text2);line-height:1.6;max-width:640px;margin-bottom:48px}
.gradient-text{color:var(--text)}
.callout{font-family:var(--font-b);font-size:clamp(20px,2.5vw,28px);font-style:italic;color:var(--text2);line-height:1.5;border-left:3px solid var(--border);padding-left:24px;margin:40px 0}

/* ══ HERO PANEL ══ */
.hero-content{max-width:800px}
.hero-eyebrow{display:inline-flex;align-items:center;gap:10px;margin-bottom:32px}
.hero-eyebrow .x-mark{font-family:var(--font-m);font-size:14px;color:var(--text3);margin:0 4px}
.hero-content h1{font-family:var(--font-b);font-size:clamp(44px,6.5vw,88px);line-height:1.02;letter-spacing:-.04em;margin-bottom:20px;font-weight:300}
.hero-content>p{font-size:clamp(15px,1.4vw,19px);color:var(--text2);line-height:1.65;max-width:580px;margin-bottom:40px}
.hero-meta{display:flex;gap:40px;flex-wrap:wrap}
.hero-meta-item{display:flex;flex-direction:column;gap:2px}
.hero-meta-item .val{font-family:var(--font-b);font-size:28px;font-weight:700;color:var(--text)}
.hero-meta-item .lbl{font-family:var(--font-b);font-size:12px;font-weight:500;color:var(--text3);text-transform:uppercase;letter-spacing:.08em}

/* ══ LOGO ROW ══ */
.logo-row{display:flex;gap:32px;align-items:center;flex-wrap:wrap;margin:32px 0}
.logo-row .lr-item{display:flex;align-items:center;gap:8px;opacity:.55;transition:opacity .3s}
.logo-row .lr-item:hover{opacity:1}
.lr-icon{width:32px;height:32px;border-radius:7px;display:flex;align-items:center;justify-content:center;font-weight:800;font-size:11px;color:#fff;flex-shrink:0;overflow:hidden}
.lr-icon img{width:100%;height:100%;object-fit:contain;padding:3px}
.lr-icon.no-pad img{padding:0;object-fit:cover;border-radius:inherit}
.brand-logo{height:18px;vertical-align:middle}
.brand-logo-lg{height:28px;vertical-align:middle}

/* ══ DATA TABLE ══ */
.data-table-wrap{background:#fff;border:1px solid var(--border);border-radius:16px;overflow:hidden;margin:32px 0}
.data-table{width:100%;border-collapse:collapse;font-size:14px}
.data-table thead{background:#f8f8f8}
.data-table th{font-family:var(--font-b);padding:14px 20px;text-align:left;font-weight:500;font-size:11px;text-transform:uppercase;letter-spacing:.08em;color:var(--text3);border-bottom:1px solid var(--border)}
.data-table td{padding:14px 20px;border-bottom:1px solid var(--border);color:var(--text2);vertical-align:top}
.data-table tr:last-child td{border-bottom:none}
.data-table tr:hover td{background:#f8f8f8;transition:background .2s}
.data-table .em{color:var(--text);font-weight:600}
.data-table .hl{color:var(--accent);font-weight:700}
@media(max-width:768px){.data-table-wrap{overflow-x:auto}}

/* ══ STAT GRID ══ */
.stat-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(220px,1fr));gap:20px;margin:32px 0}
.stat-card{padding:28px;background:#fff;border:1px solid var(--border);border-radius:16px;position:relative;overflow:hidden;transition:all .35s cubic-bezier(.22,1,.36,1)}
.stat-card::before{display:none}
.stat-card:hover{transform:translateY(-2px);box-shadow:0 4px 12px rgba(0,0,0,.06);border-color:#bbb}
.stat-val{font-family:var(--font-b);font-size:42px;font-weight:300;line-height:1;color:var(--s-color,var(--text));margin-bottom:6px}
.stat-label{font-family:var(--font-b);font-size:13px;font-weight:500;margin-bottom:4px}
.stat-desc{font-size:12px;color:var(--text3);line-height:1.5}
.mini-bar{height:4px;background:rgba(0,0,0,.06);border-radius:2px;margin-top:12px;overflow:hidden}
.mini-bar-fill{height:100%;border-radius:2px;width:0;transition:width 1.2s cubic-bezier(.22,1,.36,1)}

/* ══ QUOTE CARDS ══ */
.quotes-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(320px,1fr));gap:24px}
.q-card{background:#fff;border:1px solid var(--border);border-radius:16px;padding:28px;transition:all .35s cubic-bezier(.22,1,.36,1);cursor:pointer}
.q-card:hover{border-color:#bbb;transform:translateY(-2px);box-shadow:0 4px 12px rgba(0,0,0,.06)}
.q-mark{font-family:Georgia,serif;font-size:56px;line-height:1;color:var(--text3);opacity:.15}
.q-text{font-size:14px;line-height:1.7;color:var(--text2);font-style:italic;margin:8px 0 20px}
.q-card .q-extra{max-height:0;overflow:hidden;transition:max-height .5s cubic-bezier(.22,1,.36,1);font-size:13px;color:var(--text3);line-height:1.6}
.q-card.expanded .q-extra{max-height:200px}
.q-author{display:flex;align-items:center;gap:10px;padding-top:16px;border-top:1px solid var(--border)}
.q-avatar{width:36px;height:36px;border-radius:8px;display:flex;align-items:center;justify-content:center;font-weight:700;font-size:12px;color:#fff;flex-shrink:0}
.q-info h4{font-size:13px;font-weight:600}.q-info p{font-size:11px;color:var(--text3)}

/* ══ THESIS BLOCK ══ */
.thesis-item{display:flex;gap:20px;padding:24px;background:#fff;border:1px solid var(--border);border-radius:14px;margin-bottom:16px;transition:all .4s cubic-bezier(.22,1,.36,1);cursor:pointer}
.thesis-item:hover{border-color:#bbb;background:#fafafa}
.thesis-num{width:40px;height:40px;border-radius:10px;background:#f2f2f2;display:flex;align-items:center;justify-content:center;font-family:var(--font-m);font-size:13px;font-weight:600;color:var(--text);flex-shrink:0}
.thesis-item h3{font-size:16px;font-weight:700;margin-bottom:4px;display:flex;align-items:center;gap:8px}
.thesis-item h3 .expand-icon{font-size:12px;color:var(--text3);transition:transform .3s}
.thesis-item.expanded h3 .expand-icon{transform:rotate(180deg)}
.thesis-item p{font-size:13px;color:var(--text2);line-height:1.65}
.thesis-item .thesis-extra{max-height:0;overflow:hidden;transition:max-height .5s cubic-bezier(.22,1,.36,1);font-size:13px;color:var(--text3);line-height:1.7;margin-top:0}
.thesis-item.expanded .thesis-extra{max-height:300px;margin-top:12px}

/* ══ PARTNER CARDS ══ */
.partner-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(300px,1fr));gap:24px;margin:32px 0}
.p-card{padding:28px;background:#fff;border:1px solid var(--border);border-radius:16px;transition:all .35s cubic-bezier(.22,1,.36,1);cursor:pointer}
.p-card:hover{border-color:#bbb;transform:translateY(-2px);box-shadow:0 4px 12px rgba(0,0,0,.06)}
.p-card-head{display:flex;align-items:center;gap:12px;margin-bottom:12px}
.p-card-head .lr-icon{width:44px;height:44px;border-radius:10px;font-size:15px}
.p-card-head .name{font-size:18px;font-weight:700}
.p-card .type{font-size:11px;text-transform:uppercase;letter-spacing:.1em;color:var(--text3);margin-bottom:8px}
.p-card .desc{font-size:13px;color:var(--text2);line-height:1.6}
.p-card .p-extra{max-height:0;overflow:hidden;transition:max-height .5s cubic-bezier(.22,1,.36,1);font-size:13px;color:var(--text3);line-height:1.6}
.p-card.expanded .p-extra{max-height:200px;margin-top:12px}

/* ══ RATING DOTS ══ */
.dots{display:flex;gap:3px}
.dot{width:16px;height:5px;border-radius:3px;background:rgba(0,0,0,.08)}
.dot.on{background:var(--text)}.dot.g{background:var(--green)}.dot.o{background:var(--orange)}

/* ══ SVG DONUT ══ */
.donut-chart{width:36px;height:36px;display:inline-block;vertical-align:middle}
.donut-chart circle{fill:none;stroke-width:3;stroke-linecap:round}
.donut-chart .donut-bg{stroke:rgba(0,0,0,.08)}
.donut-chart .donut-fill{stroke:var(--accent);stroke-dasharray:0 100;transition:stroke-dasharray 1.2s cubic-bezier(.22,1,.36,1)}

/* ══ BADGES ══ */
.badge{display:inline-block;padding:3px 10px;border-radius:100px;font-size:10px;font-weight:700;letter-spacing:.04em;text-transform:uppercase}
.badge-leader{background:rgba(36,209,100,.12);color:var(--green)}
.badge-contend{background:rgba(255,122,0,.12);color:var(--orange)}
.badge-emerge{background:rgba(128,233,255,.12);color:var(--accent2)}

/* ══ RISK TABLE ══ */
.risk-row{display:grid;grid-template-columns:1fr 1fr;gap:0;border-bottom:1px solid var(--border)}
.risk-row:last-child{border-bottom:none}
.risk-cell{padding:20px 24px;font-size:13px;line-height:1.65;color:var(--text2)}
.risk-cell:first-child{border-right:1px solid var(--border);color:var(--red)}
.risk-cell strong{color:var(--text);font-weight:600;display:block;margin-bottom:4px}

/* ══ TEAM GRID ══ */
.team-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(240px,1fr));gap:24px;margin:32px 0}
.team-card{padding:24px;background:#fff;border:1px solid var(--border);border-radius:14px;transition:all .3s}
.team-card:hover{border-color:#bbb;transform:translateY(-2px)}
.team-card h4{font-size:14px;font-weight:700;margin-bottom:2px}
.team-card .role{font-size:12px;color:var(--text2);margin-bottom:8px}
.team-card p{font-size:12px;color:var(--text3);line-height:1.5}

/* ══ TIMELINE ══ */
.timeline{position:relative;padding-left:32px;margin:32px 0}
.timeline::before{content:'';position:absolute;left:8px;top:0;bottom:0;width:2px;background:var(--border)}
.timeline-item{position:relative;padding-bottom:28px;opacity:0;transform:translateX(-20px);transition:all .5s cubic-bezier(.22,1,.36,1)}
.timeline-item.tl-visible{opacity:1;transform:translateX(0)}
.timeline-item::before{content:'';position:absolute;left:-28px;top:4px;width:12px;height:12px;border-radius:50%;background:var(--text3);border:2px solid #fff;z-index:1}
.timeline-item .tl-date{font-family:var(--font-m);font-size:10px;color:var(--text3);letter-spacing:.1em;text-transform:uppercase;margin-bottom:4px}
.timeline-item h4{font-size:14px;font-weight:600;margin-bottom:2px}
.timeline-item p{font-size:12px;color:var(--text3);line-height:1.5}

/* ══ PIPELINE ══ */
.pipeline{display:flex;gap:0;margin:32px 0;overflow-x:auto;padding-bottom:8px}
.pipeline-stage{flex:1;min-width:160px;text-align:center;position:relative;padding:20px 12px}
.pipeline-stage::after{content:'';position:absolute;top:50%;right:0;width:100%;height:2px;background:var(--border);opacity:.5;z-index:0}
.pipeline-stage:last-child::after{display:none}
.pipeline-node{width:44px;height:44px;border-radius:50%;margin:0 auto 12px;display:flex;align-items:center;justify-content:center;font-family:var(--font-m);font-size:11px;font-weight:600;position:relative;z-index:1;border:2px solid var(--border);transition:all .4s}
.pipeline-stage.pl-active .pipeline-node{background:#f2f2f2;border-color:var(--text);box-shadow:none}
.pipeline-stage.pl-future .pipeline-node{opacity:.4;border-style:dashed}
.pipeline-stage h4{font-size:11px;font-weight:600;margin-bottom:4px}
.pipeline-stage p{font-size:10px;color:var(--text3);line-height:1.4}

/* ══ CTA ══ */
.cta-content{text-align:center;padding:60px 0}
.cta-content h2{font-family:var(--font-b);font-size:clamp(36px,5vw,60px);letter-spacing:-.03em;margin-bottom:16px;font-weight:300}
.cta-content p{font-size:17px;color:var(--text2);max-width:500px;margin:0 auto 20px}
.cta-footer{padding:40px 0;border-top:1px solid var(--border);font-size:12px;color:var(--text3);display:flex;justify-content:space-between;flex-wrap:wrap;gap:12px}

/* ══ NAVIGATION SIDEBAR ══ */
.deck-nav{position:fixed;left:50%;top:50%;transform:translate(-50%,-50%);z-index:30;
  width:340px;max-height:calc(100vh - 80px);
  transition:left .5s cubic-bezier(.22,1,.36,1),top .5s cubic-bezier(.22,1,.36,1),transform .5s cubic-bezier(.22,1,.36,1),width .4s cubic-bezier(.22,1,.36,1),opacity .4s,visibility .4s}
.deck-nav.hidden{opacity:0;visibility:hidden;transform:translate(-50%,-50%) scale(.95)}
/* When panel is open, slide to left sidebar position */
.deck-nav.sidebar{left:28px;top:50%;transform:translateY(-50%);width:340px}
.deck-nav-inner{background:#fff;
  border:1px solid var(--border);border-radius:20px;padding:20px 20px;
  box-shadow:0 2px 8px rgba(0,0,0,.04);
  display:flex;flex-direction:column;gap:0;max-height:calc(100vh - 80px);overflow-y:auto;overflow-x:hidden}
.nav-section{min-width:0;border-bottom:1px solid var(--border);padding:4px 0}
.nav-section:last-child{border-bottom:none}
.nav-section-title{display:flex;align-items:center;gap:8px;padding:10px 12px;
  border-radius:10px;cursor:pointer;font-family:var(--font-b);font-size:13px;font-weight:500;
  color:var(--text);transition:background .2s;user-select:none}
.nav-section-title:hover{background:rgba(0,0,0,.05)}
.nav-section-icon{width:8px;height:8px;border-radius:50%;flex-shrink:0}
.nav-chevron{font-size:10px;color:var(--text3);margin-left:auto;transition:transform .3s}
.nav-section.expanded .nav-chevron{transform:rotate(180deg)}
.nav-section-items{max-height:0;overflow:hidden;transition:max-height .4s cubic-bezier(.22,1,.36,1)}
.nav-section.expanded .nav-section-items{max-height:300px}
.nav-item{display:block;width:100%;text-align:left;padding:7px 12px 7px 28px;
  background:none;border:none;font-family:var(--font-b);font-size:12px;font-weight:300;
  color:var(--text2);cursor:pointer;border-radius:8px;transition:all .2s;
  position:relative}
.nav-item::before{content:'';position:absolute;left:14px;top:50%;transform:translateY(-50%);
  width:5px;height:5px;border-radius:50%;background:var(--nav-accent,var(--accent));opacity:.5}
.nav-item:hover{background:rgba(0,0,0,.04);color:var(--text)}
.nav-item:hover::before{opacity:1}

/* ══ RESPONSIVE ══ */
@media(max-width:768px){
  .panel-inner{padding:60px 20px 100px}
  .hero-meta{gap:24px}
  .stat-grid{grid-template-columns:1fr 1fr}
  .partner-grid{grid-template-columns:1fr}
  .quotes-grid{grid-template-columns:1fr}
  .team-grid{grid-template-columns:1fr 1fr}
  .risk-row{grid-template-columns:1fr}
  .risk-cell:first-child{border-right:none;border-bottom:1px solid var(--border)}
  .pipeline{flex-wrap:wrap}
  .pipeline-stage{min-width:120px}
  .cluster-nav{display:none}
  .back-btn{top:16px;left:16px;padding:8px 14px}
  /* Nav becomes bottom sheet on mobile */
  .deck-nav{left:0;right:0;bottom:0;top:auto;transform:none;width:100%;max-height:50vh;border-radius:0}
  .deck-nav.hidden{transform:translateY(100%);opacity:0;visibility:hidden}
  .deck-nav.sidebar{left:0;top:auto;transform:translateY(calc(100% - 56px));width:100%}
  .deck-nav-inner{border-radius:20px 20px 0 0;padding:12px 14px;max-height:50vh}
  .brand-overlay{font-size:11px;padding:4px 10px 12px;margin-bottom:4px}
  .nav-section-title{font-size:12px;padding:6px 10px}
  .nav-item{font-size:11px;padding:6px 10px 6px 24px}
  /* Panels become near-full-screen on mobile */
  #content-panels{left:0;padding:8px}
  .content-panel{top:8px;right:8px;bottom:8px;left:8px;border-radius:16px}
}
</style>
</head>
<body>

<!-- ══ LOADING SCREEN ══ -->
<div id="loader">
  <div class="loader-helix" style="perspective:400px">
    <div class="helix-strand">
      <div class="helix-node" style="top:0%;background:#7B9FE8;animation-delay:0s;margin-left:-28px"></div>
      <div class="helix-node" style="top:14%;background:#8EAFF0;animation-delay:.1s;margin-left:-20px"></div>
      <div class="helix-node" style="top:28%;background:#A3C1F5;animation-delay:.2s;margin-left:-8px"></div>
      <div class="helix-node" style="top:42%;background:#F0A0B8;animation-delay:.3s;margin-left:4px"></div>
      <div class="helix-node" style="top:56%;background:#E88DA5;animation-delay:.4s;margin-left:12px"></div>
      <div class="helix-node" style="top:70%;background:#F5C070;animation-delay:.5s;margin-left:16px"></div>
      <div class="helix-node" style="top:84%;background:#80D8C0;animation-delay:.6s;margin-left:12px"></div>
    </div>
    <div class="helix-strand">
      <div class="helix-node" style="top:0%;background:#80D8C0;animation-delay:.15s;margin-left:18px"></div>
      <div class="helix-node" style="top:14%;background:#F5C070;animation-delay:.25s;margin-left:12px"></div>
      <div class="helix-node" style="top:28%;background:#E88DA5;animation-delay:.35s;margin-left:0px"></div>
      <div class="helix-node" style="top:42%;background:#A3C1F5;animation-delay:.45s;margin-left:-12px"></div>
      <div class="helix-node" style="top:56%;background:#8EAFF0;animation-delay:.55s;margin-left:-20px"></div>
      <div class="helix-node" style="top:70%;background:#7B9FE8;animation-delay:.65s;margin-left:-24px"></div>
      <div class="helix-node" style="top:84%;background:#F0A0B8;animation-delay:.75s;margin-left:-20px"></div>
    </div>
    <!-- bridges connecting the two strands -->
    <div class="helix-bridge" style="top:3%;margin-left:-24px;animation-delay:.1s"></div>
    <div class="helix-bridge" style="top:17%;margin-left:-16px;animation-delay:.2s"></div>
    <div class="helix-bridge" style="top:31%;margin-left:-4px;animation-delay:.3s"></div>
    <div class="helix-bridge" style="top:45%;margin-left:-8px;animation-delay:.4s"></div>
    <div class="helix-bridge" style="top:59%;margin-left:-16px;animation-delay:.5s"></div>
    <div class="helix-bridge" style="top:73%;margin-left:-20px;animation-delay:.6s"></div>
    <div class="helix-bridge" style="top:87%;margin-left:-16px;animation-delay:.7s"></div>
  </div>
  <p class="loader-text" id="loaderText">Folding protein structure...</p>
  <div class="loader-bar"><div class="loader-bar-fill"></div></div>
</div>

<!-- ══ VIDEO BACKGROUND ══ -->
<div id="scene-container">
  <video id="bgVideo" autoplay muted loop playsinline preload="auto"></video>
  <div id="video-overlay"></div>
</div>

<!-- ══ BACK BUTTON ══ -->
<button class="back-btn" id="backBtn" onclick="closePanel()">
  <svg viewBox="0 0 24 24"><polyline points="15 18 9 12 15 6"></polyline></svg>
  Back
</button>

<!-- ══ CLUSTER NAV ══ -->
<div class="cluster-nav" id="clusterNav"></div>

<!-- ══ NAVIGATION SIDEBAR ══ -->
<nav class="deck-nav" id="deckNav">
  <div class="deck-nav-inner">
    <!-- Branding integrated into nav card -->
    <div class="brand-overlay" id="brandOverlay">
      <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" class="brand-logo" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em>///\\ STRIPES</span>'">
      <span class="x-mark">×</span>
      <span class="iso-logo" style="height:20px;opacity:.9">
        <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
        <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:2px"></span>
      </span>
    </div>
    <div class="nav-section expanded">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#635BFF"></span>
        Introduction
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="hero" style="--nav-accent:#635BFF">Cover</button>
        <button class="nav-item" data-target="investments" style="--nav-accent:#80E9FF">Recent Investments</button>
      </div>
    </div>
    <div class="nav-section">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#E85D75"></span>
        Industry Landscape
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="rdcrisis" style="--nav-accent:#E85D75">R&D Productivity Crisis</button>
        <button class="nav-item" data-target="trialheadwinds" style="--nav-accent:#FF7A00">Clinical Trial Headwinds</button>
        <button class="nav-item" data-target="aivalue" style="--nav-accent:#635BFF">AI Across Pharma</button>
        <button class="nav-item" data-target="rdparadigms" style="--nav-accent:#80E9FF">R&D Paradigms</button>
      </div>
    </div>
    <div class="nav-section">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#FF4D6D"></span>
        Our Perspective
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="inflection" style="--nav-accent:#FF4D6D">Pharma Inflection</button>
        <button class="nav-item" data-target="diligence" style="--nav-accent:#24D164">Market Diligence</button>
        <button class="nav-item" data-target="thesis" style="--nav-accent:#635BFF">Investment Thesis</button>
        <button class="nav-item" data-target="uvp" style="--nav-accent:#80E9FF">Unique Value Prop</button>
        <button class="nav-item" data-target="validation" style="--nav-accent:#C8A95A">Customer Validation</button>
        <button class="nav-item" data-target="competitive" style="--nav-accent:#FF5CAA">Competitive Landscape</button>
        <button class="nav-item" data-target="growth" style="--nav-accent:#24D164">Growth Vectors</button>
        <button class="nav-item" data-target="risks" style="--nav-accent:#FF7A00">Risks & Mitigants</button>
      </div>
    </div>
    <div class="nav-section">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#635BFF"></span>
        Our Team
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="team" style="--nav-accent:#635BFF">Stripes Overview</button>
        <button class="nav-item" data-target="scaleteam" style="--nav-accent:#24D164">Scale Team</button>
        <button class="nav-item" data-target="healthcare" style="--nav-accent:#FF6B9D">Healthcare Expertise</button>
        <button class="nav-item" data-target="ops" style="--nav-accent:#80E9FF">Operating Partners</button>
        <button class="nav-item" data-target="councils" style="--nav-accent:#FF5CAA">Advisory Councils</button>
        <button class="nav-item" data-target="end" style="--nav-accent:#635BFF">Thank You</button>
      </div>
    </div>
  </div>
</nav>

<!-- ══ CONTENT PANELS ══ -->
<div id="content-panels">

  <!-- HERO -->
  <div class="content-panel" data-node="hero">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Introduction</span><span class="bc-sep">›</span><span style="color:var(--accent)">Cover</span></div>
      <div class="hero-content">
        <div class="hero-eyebrow">
          <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" class="brand-logo-lg" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em>///\\ STRIPES</span>'">
          <span class="x-mark">×</span>
          <span class="iso-logo" style="height:28px">
            <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
            <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:3px"></span>
          </span>
        </div>
        <h1>Reimagining<br><span class="gradient-text">Drug Discovery</span><br>with AI</h1>
        <p>Stripes is an NYC-based growth equity firm led by entrepreneurs and operators. We invest in and actively support best-in-class, category-defining companies. We believe Isomorphic Labs will revolutionize drug discovery.</p>
        <div class="hero-meta">
          <div class="hero-meta-item"><span class="val" data-count="8" data-prefix="$" data-suffix="B">$0B</span><span class="lbl">AUM</span></div>
          <div class="hero-meta-item"><span class="val">Fund VII</span><span class="lbl">Current Fund</span></div>
          <div class="hero-meta-item"><span class="val">NYC</span><span class="lbl">Headquartered</span></div>
        </div>
        <div class="logo-row" style="margin-top:40px">
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#6161FF"><img src="https://www.google.com/s2/favicons?domain=monday.com&sz=128" alt="monday.com"></div><div class="lr-name">monday.com</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#1DBE72"><img src="https://www.google.com/s2/favicons?domain=ramp.com&sz=128" alt="Ramp"></div><div class="lr-name">Ramp</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#000;border:1px solid #333"><img src="https://www.google.com/s2/favicons?domain=a24films.com&sz=128" alt="A24"></div><div class="lr-name">A24</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#2C56DD"><img src="https://www.google.com/s2/favicons?domain=dataiku.com&sz=128" alt="Dataiku"></div><div class="lr-name">Dataiku</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#000;border:1px solid #333"><img src="https://www.google.com/s2/favicons?domain=on-running.com&sz=128" alt="On Running"></div><div class="lr-name">On Running</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#4C4AE6"><img src="https://www.google.com/s2/favicons?domain=snyk.io&sz=128" alt="Snyk"></div><div class="lr-name">Snyk</div></div>
        </div>
      </div>
    </div>
  </div>

  <!-- RECENT INVESTMENTS -->
  <div class="content-panel" data-node="investments">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Introduction</span><span class="bc-sep">›</span><span style="color:#80E9FF">Recent Investments</span></div>
      <div class="label">Category-Defining Investments</div>
      <h2 class="sec-title">Our recent investments</h2>
      <p class="sec-sub">Stripes partners with founders building n-of-1, category-defining companies with enormous opportunity. We look for <strong style="color:var(--text)">amazing products</strong> with <strong style="color:var(--text)">amazing market opportunities.</strong></p>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th>Company</th><th>Overview</th><th>Round</th></tr></thead>
          <tbody>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#FF3621;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=databricks.com&sz=128" alt="DB"></div><span class="em">Databricks</span></div></td><td>Leading data infrastructure platform</td><td class="hl">$10B, Dec 2024</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#1DBE72;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=ramp.com&sz=128" alt="Ramp"></div><span class="em">Ramp</span></div></td><td>Finance automation platform</td><td class="hl">$150M, Dec 2024</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#0047AB;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=appliedintuition.com&sz=128" alt="AI"></div><span class="em">Applied Intuition</span></div></td><td>Autonomous mobility solutions</td><td class="hl">Undisclosed</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#1E88E5;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=flocksafety.com&sz=128" alt="FS"></div><span class="em">Flock Safety</span></div></td><td>AI-powered public safety</td><td class="hl">$275M, Mar 2025</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#C45A3C;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=vuoriclothing.com&sz=128" alt="V"></div><span class="em">Vuori</span></div></td><td>Premium athleisure brand</td><td class="hl">$825M, Nov 2024</td></tr>
          </tbody>
        </table>
      </div>
      <div class="callout">We believe Isomorphic Labs will be a highly sought-after business for public market investors — like On Running (NYSE: ONON, $19.5B) and Monday.com (NASDAQ: MNDY, $14.9B).</div>
    </div>
  </div>

  <!-- R&D PRODUCTIVITY CRISIS -->
  <div class="content-panel" data-node="rdcrisis">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#E85D75,#FF7A00)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:#E85D75">R&D Productivity Crisis</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">R&D is getting more expensive<br>without <span class="gradient-text">getting faster</span></h2>
      <p class="sec-sub">Convergence of challenges require new approaches to R&D. Structural pressures across pharma are creating a generational opening for AI-native drug discovery.</p>
      <div class="data-table-wrap" style="margin-top:32px">
        <table class="data-table">
          <thead><tr><th>Metric</th><th>Then</th><th>Now</th><th>Trend</th></tr></thead>
          <tbody>
            <tr><td class="em">Avg. annual R&D expenditure (top 15)</td><td>$5.3B (2011-15)</td><td><span class="hl">$6.0B</span> (2016-20)</td><td style="color:var(--red)">&#9650; Rising</td></tr>
            <tr><td class="em">Avg. years to complete Phase 2 & 3</td><td>6.5 years</td><td><span class="hl">7.1 years</span></td><td style="color:var(--red)">&#9650; Worsening</td></tr>
          </tbody>
        </table>
      </div>
      <h3 style="font-size:20px;margin:40px 0 20px;font-family:var(--font-g);font-weight:700">Compounding Challenges &amp; Delays</h3>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th>Increasing Pressure</th><th>Challenging Backdrop</th><th>Resulting Impact</th></tr></thead>
          <tbody>
            <tr><td><span class="hl">50%</span> decrease in years of MOA exclusivity (8 yrs in 2000-04 vs. 4 yrs in 2016+)</td><td><span class="hl">53%</span> of sites indicate insufficient bandwidth to run trials</td><td><span class="hl">22%</span> of trials have delays >40%</td></tr>
            <tr><td><span class="hl">40%</span> increase in patient trial slots in oncology (2016-21)</td><td><span class="hl">56%</span> increase in trial complexity vs. 3 years ago</td><td><span class="hl">80%</span> of sponsors not meeting DEI goals</td></tr>
          </tbody>
        </table>
      </div>
      <div class="callout" style="margin-top:32px;border-left:3px solid #E85D75"><strong>Isomorphic Labs positioning:</strong> AI-driven drug discovery can compress timelines, reduce trial complexity, and improve hit rates at the earliest stages — addressing the root causes of R&D productivity decline before costs compound through clinical development.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Schumacher "Analysis of pharma R&D productivity" (Oct 2023); Bain "Clinical Trials at a Crossroads" (Jan 2023); Bain "Benchmarking and TSR" (Oct 2023)</p>
    </div>
  </div>

  <!-- CLINICAL TRIAL HEADWINDS -->
  <div class="content-panel" data-node="trialheadwinds">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF7A00,#C8A95A)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:#FF7A00">Clinical Trial Headwinds</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">Big pharma pulling back on trials<br><span class="gradient-text">smaller players filling the gap</span></h2>
      <p class="sec-sub">Top pharma companies are rationalizing trial portfolios — while smaller, more nimble companies (including AI-native biotechs) are driving the majority of new clinical activity.</p>
      <div class="data-table-wrap" style="margin-top:32px">
        <table class="data-table">
          <thead><tr><th>Year</th><th>Total Starts</th><th>"Others" Share</th><th>Growth</th></tr></thead>
          <tbody>
            <tr><td class="em">2015</td><td>3,951</td><td>53%</td><td rowspan="2" style="vertical-align:middle;color:var(--green)">+6% p.a.</td></tr>
            <tr><td class="em">2020</td><td>5,213</td><td>69%</td></tr>
            <tr><td class="em">2021</td><td><span class="hl">6,368</span> (peak)</td><td>72%</td><td style="color:var(--green)">+7% p.a.</td></tr>
            <tr><td class="em">2024</td><td>5,614</td><td><span class="hl">75%</span></td><td style="color:var(--red)">-3% p.a.</td></tr>
          </tbody>
        </table>
      </div>
      <div class="stat-grid" style="margin-top:32px">
        <div class="stat-card" style="--s-color:var(--red)"><div class="stat-val" data-count="4" data-prefix="-" data-suffix="%">0%</div><div class="stat-label">Top 10 Pharma CAGR (2022-24)</div><div class="stat-desc">Largest companies leading the decline, rationalizing portfolios</div><div class="mini-bar"><div class="mini-bar-fill" data-width="40%" style="background:var(--red)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--orange)"><div class="stat-val" data-count="75" data-suffix="%">0%</div><div class="stat-label">"Others" Share of Trial Starts</div><div class="stat-desc">Up from 53% in 2015 — smaller companies driving clinical activity</div><div class="mini-bar"><div class="mini-bar-fill" data-width="75%" style="background:var(--orange)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--accent)"><div class="stat-val" data-count="86" data-suffix="%">0%</div><div class="stat-label">Facing Cost Scrutiny</div><div class="stat-desc">Budget pressure pushing pharma to seek external innovation partners</div><div class="mini-bar"><div class="mini-bar-fill" data-width="86%" style="background:var(--accent)"></div></div></div>
      </div>
      <div class="callout" style="margin-top:32px;border-left:3px solid #FF7A00"><strong>Why this matters for Isomorphic:</strong> As big pharma consolidates trial activity and prioritizes capital efficiency, demand for AI platforms that de-risk early discovery and compress preclinical timelines will only accelerate. Isomorphic's partnerships with Lilly and Novartis position it as a critical infrastructure layer for this new model.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Citeline Trialtrove as of July 2025; PharmaCo rankings by reported 2024 revenue</p>
    </div>
  </div>

  <!-- AI ACROSS PHARMA VALUE CHAIN -->
  <div class="content-panel" data-node="aivalue">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#24D164)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:var(--accent)">AI Across Pharma</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">AI adoption is scaling rapidly<br><span class="gradient-text">>50% of pharma have at least a POC</span></h2>
      <p class="sec-sub">The industry has moved past experimentation — the question is no longer "if" but "how fast."</p>
      <div class="data-table-wrap" style="margin-top:32px">
        <table class="data-table">
          <thead><tr><th>Stage</th><th>Company</th><th>Use Case</th><th>Detail</th></tr></thead>
          <tbody>
            <tr><td><span style="color:var(--accent);font-weight:600">Discovery</span></td><td class="em">Moderna + IBM</td><td>mRNA Candidate ID</td><td>Using GenAI to rapidly identify new mRNA vaccine candidates</td></tr>
            <tr><td><span style="color:var(--accent);font-weight:600">Discovery</span></td><td class="em">AstraZeneca</td><td>ML Pattern Recognition</td><td>Partnering with academia to spot patterns between healthy, diseased, and drug-treated tissue</td></tr>
            <tr><td><span style="color:var(--green);font-weight:600">Development</span></td><td class="em">Sanofi</td><td>Clinical Trial Optimization</td><td>Plai app identifies promising trial locations and participant information</td></tr>
            <tr><td><span style="color:var(--green);font-weight:600">Development</span></td><td class="em">Eli Lilly + Yseop</td><td>Study Report Automation</td><td>Automating patient narratives and clinical study reports</td></tr>
            <tr><td><span style="color:var(--green);font-weight:600">Development</span></td><td class="em">Pfizer + Concreto</td><td>Regulatory Filing</td><td>Accelerating outcome studies and regulatory submissions</td></tr>
            <tr><td><span style="color:var(--orange);font-weight:600">Supply</span></td><td class="em">Eli Lilly</td><td>Robotic Process AI</td><td>AI solutions to automate robotic manufacturing and identify inefficiencies</td></tr>
            <tr><td><span style="color:var(--pink);font-weight:600">Launch</span></td><td class="em">GSK + Tempus</td><td>Personalized Treatment</td><td>AI-enabled platform for personalized treatment; improving trial design</td></tr>
            <tr><td><span style="color:var(--pink);font-weight:600">Launch</span></td><td class="em">Novartis + Aktana</td><td>HCP Engagement</td><td>Better segmenting, engaging, and following up with healthcare providers</td></tr>
          </tbody>
        </table>
      </div>
      <div class="callout" style="margin-top:32px;border-left:3px solid var(--accent)"><strong>Discovery remains the highest-value, hardest-to-crack frontier,</strong> and Isomorphic Labs' AlphaFold-derived models give it a structural advantage in the most impactful segment of the value chain.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Bain GenAI in Pharma Survey (N=100), Sept 2023; Company websites and earnings calls</p>
    </div>
  </div>

  <!-- EMERGING R&D PARADIGMS -->
  <div class="content-panel" data-node="rdparadigms">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:var(--accent2)">R&D Paradigms</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">Three macro shifts are reshaping<br><span class="gradient-text">how pharma discovers drugs</span></h2>
      <p class="sec-sub">From new modalities to decentralized trials to ecosystem partnerships — the R&D landscape is transforming.</p>
      <div style="margin-top:36px">
        <div style="margin-bottom:36px">
          <h3 style="font-size:20px;font-family:var(--font-g);margin-bottom:16px"><span style="display:inline-block;width:28px;height:28px;border-radius:50%;background:var(--accent);color:#fff;text-align:center;line-height:28px;font-family:var(--font-b);font-size:13px;font-weight:600;margin-right:10px;vertical-align:middle">1</span>Rapid Expansion of Treatment Modalities</h3>
          <ul style="list-style:none;display:flex;flex-direction:column;gap:10px;padding-left:38px">
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--accent)">&#8226;</span>Massive expansion from frontier (CRISPR, microbiome) to emerging (gene/cell therapies, bispecific antibodies) to mature (mAbs, small molecule)</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--accent)">&#8226;</span>Significantly more complex choice set for R&D orgs to prioritize across TAs, modalities, and MOAs</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--accent)">&#8226;</span>Ramifications cascade across the entire value chain: manufacturing, distribution, and customer engagement</li>
          </ul>
        </div>
        <div style="margin-bottom:36px">
          <h3 style="font-size:20px;font-family:var(--font-g);margin-bottom:16px"><span style="display:inline-block;width:28px;height:28px;border-radius:50%;background:var(--green);color:#fff;text-align:center;line-height:28px;font-family:var(--font-b);font-size:13px;font-weight:600;margin-right:10px;vertical-align:middle">2</span>New Clinical Development Paradigms</h3>
          <ul style="list-style:none;display:flex;flex-direction:column;gap:10px;padding-left:38px">
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--green)">&#8226;</span>Disruption of traditional Phase I &#8594; II &#8594; III paradigm — adaptive trial designs, fast-tracking, post-market evidence</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--green)">&#8226;</span>Growing adoption of decentralized / virtualized trial designs, accelerated by persistent site resourcing challenges</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--green)">&#8226;</span>Increased blending of clinical and real-world data to reduce costs (e.g., digital twins)</li>
          </ul>
        </div>
        <div style="margin-bottom:36px">
          <h3 style="font-size:20px;font-family:var(--font-g);margin-bottom:16px"><span style="display:inline-block;width:28px;height:28px;border-radius:50%;background:var(--pink);color:#fff;text-align:center;line-height:28px;font-family:var(--font-b);font-size:13px;font-weight:600;margin-right:10px;vertical-align:middle">3</span>Diverse Ecosystem Engagement Models</h3>
          <ul style="list-style:none;display:flex;flex-direction:column;gap:10px;padding-left:38px">
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--pink)">&#8226;</span>Increasing growth and maturity in pharma-enabling ecosystem, seeded by recent venture funding boom</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--pink)">&#8226;</span>Expansion of collaboration models — academia, startups, big tech, CRO/CDMO</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--pink)">&#8226;</span>Managing complex ecosystem partnerships has become a core competency</li>
          </ul>
        </div>
      </div>
      <div class="callout" style="border-left:3px solid var(--accent2)"><strong>Isomorphic sits at the intersection of all three shifts:</strong> AlphaFold 3 enables work across modalities (platform play); AI-designed molecules reduce clinical cost and time; partnerships with Lilly and Novartis represent the gold-standard AI-pharma collaboration model.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Bain R&D Analysis; Industry participant interviews</p>
    </div>
  </div>

  <!-- PHARMA INFLECTION -->
  <div class="content-panel" data-node="inflection">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF4D6D,#FF7A00)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#FF4D6D">Pharma Inflection</span></div>
      <div class="label">Market Thesis</div>
      <h2 class="sec-title">The pharma industry is at<br>an <span class="gradient-text">inflection point</span></h2>
      <p class="sec-sub">Pharma is under unprecedented pressure to do more with less — creating a "burning platform" for AI-enabled drug discovery.</p>
      <div class="stat-grid">
        <div class="stat-card" style="--s-color:var(--accent)"><div class="stat-val" data-count="351" data-prefix="$" data-suffix="B">$0B</div><div class="stat-label">Global Pharma R&D Spend</div><div class="stat-desc">Growth decelerating from ~5% to 2–3% "new normal"</div><div class="mini-bar"><div class="mini-bar-fill" data-width="85%" style="background:var(--accent)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--red)"><div class="stat-val" data-count="86" data-suffix="%">0%</div><div class="stat-label">Cost Scrutiny</div><div class="stat-desc">Clinical dev leaders report increased cost scrutiny on programs</div><div class="mini-bar"><div class="mini-bar-fill" data-width="86%" style="background:var(--red)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--orange)"><div class="stat-val" data-count="75" data-prefix="~" data-suffix="%">0%</div><div class="stat-label">Revenue at Risk</div><div class="stat-desc">Top 20 pharma revenue at risk from patent cliffs & IRA pricing</div><div class="mini-bar"><div class="mini-bar-fill" data-width="75%" style="background:var(--orange)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--pink)"><div class="stat-val" data-count="7.1" data-suffix="yr" data-decimals="1">0yr</div><div class="stat-label">Phase 2/3 Timelines</div><div class="stat-desc">Extended from 6.5 years despite growing R&D spend</div><div class="mini-bar"><div class="mini-bar-fill" data-width="71%" style="background:var(--pink)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--accent2)"><div class="stat-val" data-count="3" data-prefix="-" data-suffix="%" data-decimals="0">0%</div><div class="stat-label">Trial Starts p.a.</div><div class="stat-desc">Since 2022 — sponsors becoming more selective</div><div class="mini-bar"><div class="mini-bar-fill" data-width="30%" style="background:var(--accent2)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--green)"><div class="stat-val" data-count="50" data-suffix="%">0%</div><div class="stat-label">MOA Window Shrunk</div><div class="stat-desc">From ~8 years to ~4 years — speed-to-market critical</div><div class="mini-bar"><div class="mini-bar-fill" data-width="50%" style="background:var(--green)"></div></div></div>
      </div>
      <h3 style="font-size:20px;margin:48px 0 20px;font-family:var(--font-g);font-weight:700">Pharma's Response: Embracing AI</h3>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th>Finding</th><th>Detail</th></tr></thead>
          <tbody>
            <tr><td class="em">Top 20 Pharma AI Adoption</td><td><span class="hl">50%</span> of Top 20 Pharma and <span class="hl">55%</span> of $1B–$10B companies prioritize tool adoption</td></tr>
            <tr><td class="em">AI POC Penetration</td><td>>50% have POC for AI in R&D; only <span class="hl">15%</span> in full rollout — massive whitespace</td></tr>
            <tr><td class="em">Vendor Scrutiny</td><td><span class="hl">41%</span> of sponsors being more cost-conscious with vendors</td></tr>
            <tr><td class="em">AI Governance</td><td>Pharma restricting AI to approved use cases — favors <strong style="color:var(--text)">secure, enterprise-grade platforms</strong> like Isomorphic</td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- MARKET DILIGENCE -->
  <div class="content-panel" data-node="diligence">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#24D164,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#24D164">Market Diligence</span></div>
      <div class="label">Market Diligence</div>
      <h2 class="sec-title">What we heard from<br>customers & experts</h2>
      <p class="sec-sub">Stripes conducted expert calls with senior pharma and biotech leaders to validate Isomorphic's competitive position.</p>
      <div class="logo-row" style="margin-bottom:40px">
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#E21937"><img src="https://www.google.com/s2/favicons?domain=lilly.com&sz=128" alt="Eli Lilly"></div><div class="lr-name">Eli Lilly</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#0460A9"><img src="https://www.google.com/s2/favicons?domain=novartis.com&sz=128" alt="Novartis"></div><div class="lr-name">Novartis</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#008CCE"><img src="https://www.google.com/s2/favicons?domain=abbott.com&sz=128" alt="Abbott"></div><div class="lr-name">Abbott Labs</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#C8A95A"><img src="https://www.google.com/s2/favicons?domain=elcompanies.com&sz=128" alt="Estée Lauder"></div><div class="lr-name">Estée Lauder</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#8E24AA"><img src="https://www.google.com/s2/favicons?domain=astrazeneca.com&sz=128" alt="AstraZeneca"></div><div class="lr-name">AstraZeneca</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#E31837"><img src="https://www.google.com/s2/favicons?domain=takeda.com&sz=128" alt="Takeda"></div><div class="lr-name">Takeda</div></div>
      </div>
      <div class="quotes-grid">
        <div class="q-card" onclick="toggleExpand(this)">
          <div class="q-mark">"</div>
          <div class="q-text">Among these five companies, I would definitely say Isomorphic Labs and Insilico Medicine would come out at the top. Isomorphic has multiple things under their control which keep them at the top.</div>
          <div class="q-extra">The combination of DeepMind's AI capabilities with deep biological domain expertise creates a unique advantage that no competitor can easily replicate. Their holistic approach to molecular modeling sets them apart.</div>
          <div class="q-author"><div class="q-avatar" style="background:linear-gradient(135deg,#635BFF,#80E9FF)">AB</div><div class="q-info"><h4>Former Head, Global Data Science CoE</h4><p>Abbott Laboratories</p></div></div>
        </div>
        <div class="q-card" onclick="toggleExpand(this)">
          <div class="q-mark">"</div>
          <div class="q-text">John Jumper brought accuracy up from 57% to 86%. Demis Hassabis also unorthodox. These two are outliers — rare talent not typically found in biopharma.</div>
          <div class="q-extra">The Nobel Prize recognition for AlphaFold validates the fundamental scientific breakthrough. This level of talent attraction is a significant competitive moat for the company.</div>
          <div class="q-author"><div class="q-avatar" style="background:linear-gradient(135deg,#24D164,#4ECDC4)">LY</div><div class="q-info"><h4>Senior Director, R&D Strategy</h4><p>Eli Lilly & Co</p></div></div>
        </div>
        <div class="q-card" onclick="toggleExpand(this)">
          <div class="q-mark">"</div>
          <div class="q-text">Like Isomorphic more, to be honest. More comfortable using it, more comfortable looking at the target, understanding the binding. Ease of using it a lot better.</div>
          <div class="q-extra">A current paying customer actively using the platform for dermatology research, demonstrating real commercial traction beyond traditional pharma markets.</div>
          <div class="q-author"><div class="q-avatar" style="background:linear-gradient(135deg,#FF5CAA,#FF8E53)">EL</div><div class="q-info"><h4>Director & Assoc. Research Fellow</h4><p>Estée Lauder — Current Customer</p></div></div>
        </div>
      </div>
    </div>
  </div>

  <!-- INVESTMENT THESIS -->
  <div class="content-panel" data-node="thesis">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:var(--accent)">Investment Thesis</span></div>
      <div class="label">Investment Thesis</div>
      <h2 class="sec-title">Why we believe in<br><span class="gradient-text">Isomorphic Labs</span></h2>
      <p class="sec-sub">A category-defining company with an amazing product in a market worth winning.</p>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">01</div><div><h3>Best-in-Class AI for Drug Discovery <span class="expand-icon">▾</span></h3><p>AlphaFold 2 achieved <strong>86% experimental accuracy</strong> in protein structure prediction — up from 40% prior state-of-art — declared "solved" by competition organizers.</p><div class="thesis-extra">Proprietary models (AlphaFold 2/3, Alpha Genome) represent a holistic approach using diffusion models to generate molecules satisfying all desired properties. This approach is fundamentally different and more powerful than the fragmented tools used by competitors.</div></div></div>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">02</div><div><h3>Massive Market Opportunity <span class="expand-icon">▾</span></h3><p>Global pharma R&D spend is <strong>$351B</strong> and growing, but productivity declining. Phase 2/3 timelines extended to 7.1 years while MOA exclusivity windows halved.</p><div class="thesis-extra">86% of clinical dev leaders face increased cost scrutiny — urgent demand for AI platforms. Drug discovery represents ~40% of drug development value, with the remaining 60% representing further expansion opportunity.</div></div></div>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">03</div><div><h3>Powerful Strategic Advantages <span class="expand-icon">▾</span></h3><p>Alphabet/DeepMind lineage provides unmatched talent — John Jumper (AlphaFold 2 inventor, Nobel Prize) and Demis Hassabis are "outliers — rare talent not found in biopharma."</p><div class="thesis-extra">Major pharma partnerships with Eli Lilly and Novartis validate platform quality. These partnerships provide both revenue and access to proprietary data that continuously improves the AI models.</div></div></div>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">04</div><div><h3>Clear Growth Levers <span class="expand-icon">▾</span></h3><p>Expansion from protein structure prediction → small molecule design → ADMET optimization → clinical pharmacology.</p><div class="thesis-extra">Platform potential across biologics (antibodies, ADCs). Shift from subscription to milestone- and royalty-based economics as pipeline matures. Proprietary pipeline creates asymmetric upside.</div></div></div>
    </div>
  </div>

  <!-- UNIQUE VALUE PROP -->
  <div class="content-panel" data-node="uvp">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#80E9FF">Unique Value Prop</span></div>
      <div class="label">Competitive Moat</div>
      <h2 class="sec-title">What sets Isomorphic apart</h2>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th style="width:200px">Dimension</th><th>Our Perspective</th><th>Market Commentary</th></tr></thead>
          <tbody>
            <tr><td class="em">DeepMind-Caliber AI</td><td>Foundation in AlphaFold, generalized to broader molecular modeling. Holistic diffusion-based approach. Trained on validated X-ray crystallography and NMR data.</td><td style="font-style:italic;color:var(--text3)">"Models are way ahead because they approach the entire problem holistically" — Abbott Labs</td></tr>
            <tr><td class="em">Pipeline Breadth</td><td>Spans target ID, hit finding, lead optimization, ADMET, binding dynamics, co-folding. Aspires to predict full clinical pharmacology.</td><td style="font-style:italic;color:var(--text3)">"Will aspire to predict affinities, clinical pharmacology, whole ADMET properties" — Eli Lilly</td></tr>
            <tr><td class="em">World-Class Team</td><td>Demis Hassabis (Nobel Prize) & John Jumper lead a team combining frontier AI + deep biology. Attracts top talent from both AI and biopharma.</td><td style="font-style:italic;color:var(--text3)">"These two are outliers — rare talent not typically found in biopharma" — Eli Lilly</td></tr>
            <tr><td class="em">Superior UX</td><td>Actionable insights for molecular screening, binding analysis, and target characterization with intuitive interface.</td><td style="font-style:italic;color:var(--text3)">"More user-friendly… saving a lot of time… giving us new chemical space" — Estée Lauder</td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- ESTÉE LAUDER VALIDATION -->
  <div class="content-panel" data-node="validation">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#C8A95A,#FF7A00)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#C8A95A">Customer Validation</span></div>
      <div class="label">Customer Validation</div>
      <h2 class="sec-title"><span style="display:inline-flex;align-items:center;gap:12px"><span class="lr-icon no-pad" style="background:#C8A95A;display:inline-flex;width:40px;height:40px;border-radius:10px"><img src="https://www.google.com/s2/favicons?domain=elcompanies.com&sz=128" alt="EL"></span> Estée Lauder</span> — AI Discovery in Action</h2>
      <p class="sec-sub">Real-world platform adoption for dermatology R&D demonstrates commercial traction beyond traditional pharma.</p>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th style="width:160px">Dimension</th><th>Customer Feedback</th></tr></thead>
          <tbody>
            <tr><td class="em">Time-to-Insight</td><td>"Saving a lot of time. Can screen pretty fast a bunch of molecules and understand whether or not they have relevancy to a target of interest."</td></tr>
            <tr><td class="em">Differentiation</td><td>"Unlike other software, Isomorphic is a little bit more clear in depth in terms of what types of binding capabilities certain molecules have."</td></tr>
            <tr><td class="em">New Chemical Space</td><td>"Giving us new chemical space to find different molecules. Rather than probing through traditional methods, we can speed up doing things in silico."</td></tr>
            <tr><td class="em">Preference</td><td>"Like Isomorphic more, to be honest. More comfortable using it." <span style="color:var(--text3)">(vs. Insilico Medicine, Profluent, Generative Biologics)</span></td></tr>
            <tr><td class="em">Duration & Spend</td><td>~8 months active use; <span class="hl">~$100K+</span> subscription, deployed globally</td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- COMPETITIVE LANDSCAPE -->
  <div class="content-panel" data-node="competitive">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF5CAA,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#FF5CAA">Competitive Landscape</span></div>
      <div class="label">Competitive Landscape</div>
      <h2 class="sec-title">Leading the AI drug<br>discovery race</h2>
      <div class="data-table-wrap" style="overflow-x:auto">
        <table class="data-table" style="min-width:900px">
          <thead><tr><th>Company</th><th>AI Sophistication</th><th>Partnerships</th><th>Data/Compute Moat</th><th>Platform UX</th><th>Status</th></tr></thead>
          <tbody>
            <tr>
              <td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:linear-gradient(135deg,#635BFF,#80E9FF);width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=isomorphiclabs.com&sz=128" alt="ISO"></div><span class="em">Isomorphic Labs</span></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div></div></td>
              <td><div style="display:flex;gap:4px;flex-wrap:wrap"><div class="lr-icon no-pad" style="background:#E21937;width:20px;height:20px;border-radius:4px"><img src="https://www.google.com/s2/favicons?domain=lilly.com&sz=128" alt="LLY"></div><div class="lr-icon no-pad" style="background:#0460A9;width:20px;height:20px;border-radius:4px"><img src="https://www.google.com/s2/favicons?domain=novartis.com&sz=128" alt="NVS"></div></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div></div></td>
              <td><span class="badge badge-leader">Leader</span></td>
            </tr>
            <tr>
              <td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#FF6B6B;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=insilico.com&sz=128" alt="INS"></div><span class="em">Insilico Medicine</span></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div></div></td>
              <td>Multiple clinical trials</td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><span class="badge badge-contend">Contender</span></td>
            </tr>
            <tr>
              <td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#00BCD4;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=recursion.com&sz=128" alt="RX"></div><span class="em">Recursion</span></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><div style="display:flex;gap:4px"><div class="lr-icon no-pad" style="background:#1D71B8;width:20px;height:20px;border-radius:4px"><img src="https://www.google.com/s2/favicons?domain=roche.com&sz=128" alt="Roche"></div></div> Roche/Genentech, Bayer</td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><span class="badge badge-contend">Contender</span></td>
            </tr>
            <tr>
              <td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#667eea;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=chaidiscovery.com&sz=128" alt="CH"></div><span class="em">Chai Discovery</span></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td>Limited</td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><span class="badge badge-emerge">Emerging</span></td>
            </tr>
            <tr>
              <td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#6C63FF;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=schrodinger.com&sz=128" alt="SD"></div><span class="em">Schrödinger</span></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td>Broad pharma client base</td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><div class="dots"><div class="dot on"></div><div class="dot on"></div><div class="dot on"></div><div class="dot"></div><div class="dot"></div></div></td>
              <td><span class="badge badge-contend">Contender</span></td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- GROWTH OPPORTUNITIES -->
  <div class="content-panel" data-node="growth">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#24D164,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#24D164">Growth Vectors</span></div>
      <div class="label">Growth Vectors</div>
      <h2 class="sec-title">Significant growth<br>opportunities lie ahead</h2>

      <!-- Drug Discovery Pipeline Timeline -->
      <h3 style="font-size:18px;font-family:var(--font-g);font-weight:700;margin:32px 0 8px">Drug Discovery Pipeline</h3>
      <p style="font-size:13px;color:var(--text3);margin-bottom:16px">Current capabilities and expansion roadmap</p>
      <div class="pipeline">
        <div class="pipeline-stage pl-active"><div class="pipeline-node">1</div><h4>Target ID</h4><p>AlphaFold structure prediction</p></div>
        <div class="pipeline-stage pl-active"><div class="pipeline-node">2</div><h4>Hit Finding</h4><p>Molecular screening & generation</p></div>
        <div class="pipeline-stage pl-active"><div class="pipeline-node">3</div><h4>Lead Optimization</h4><p>Property optimization</p></div>
        <div class="pipeline-stage pl-active"><div class="pipeline-node">4</div><h4>ADMET</h4><p>Absorption, distribution, metabolism</p></div>
        <div class="pipeline-stage pl-future"><div class="pipeline-node">5</div><h4>Clinical Pharm</h4><p>Digital twins, trial design</p></div>
      </div>

      <div style="margin-top:40px">
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(128,233,255,.1);color:var(--accent2)">→</div><div><h3>Platform Expansion <span class="expand-icon">▾</span></h3><p>Expand from small molecules into <strong>biologics</strong> (antibodies, ADCs, immunotherapies) — the largest and fastest-growing segments.</p><div class="thesis-extra">Multi-modal AI combining structural biology, genomics, multi-omics, and real-world evidence. Drug development (60% of total value) remains largely unaddressed — opportunity for digital twins and trial optimization.</div></div></div>
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(36,209,100,.1);color:var(--green)">→</div><div><h3>Pharma Partnership Expansion <span class="expand-icon">▾</span></h3><p>Deepen existing Eli Lilly & Novartis deals — expanded therapeutic areas, milestone/royalty triggers.</p><div class="thesis-extra">Partnerships provide dual advantage: AI tech stack access for pharma + proprietary wet/dry lab data that improves models. M&A structures shifting to smaller, milestone-heavy transactions — perfectly aligned.</div></div></div>
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(255,92,170,.1);color:var(--pink)">→</div><div><h3>Proprietary Pipeline Optionality <span class="expand-icon">▾</span></h3><p>Internal drug candidates create <strong>asymmetric upside</strong>. Precedent EV for "very good quality" Phase 3 assets has <strong>doubled since 2021 to $3.4B</strong>.</p><div class="thesis-extra">Modality acquisition precedents: Gilead/Kite $11.9B, Novartis/AveXis $8.7B, Celgene/Juno $9B.</div></div></div>
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(255,122,0,.1);color:var(--orange)">→</div><div><h3>Technical Moat Deepening <span class="expand-icon">▾</span></h3><p>All new DeepMind AI models flow to Isomorphic. Feedback loops from pharma partnerships accelerate model improvement.</p><div class="thesis-extra">The ultimate differentiator: clinical outcomes — "90% of drug candidates fail. What will differentiate is whenever a candidate survives rigorous clinical development with more approvals."</div></div></div>
      </div>
    </div>
  </div>

  <!-- RISKS & MITIGANTS -->
  <div class="content-panel" data-node="risks">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF7A00,#FF4D6D)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#FF7A00">Risks & Mitigants</span></div>
      <div class="label">Key Risks & Mitigants</div>
      <h2 class="sec-title">Balanced perspective</h2>
      <div class="data-table-wrap">
        <div class="risk-row"><div class="risk-cell"><strong>Clinical Validation Pending</strong>90% of drug candidates fail; Isomorphic still preclinical while Insilico is in clinical trials</div><div class="risk-cell">Fundamentally deeper modeling approach should translate to better clinical success. Lilly/Novartis partnerships provide resources and data to accelerate.</div></div>
        <div class="risk-row"><div class="risk-cell"><strong>End-to-End Gap</strong>Drug discovery is ~40% of value; development (60%) not yet addressed</div><div class="risk-cell">Clear roadmap into multi-omics, RWE, digital twins. Complementary partnerships (e.g., Unlearn.ai) could accelerate.</div></div>
        <div class="risk-row"><div class="risk-cell"><strong>Competitive Intensity</strong>Multiple well-funded AI companies; pharma building in-house</div><div class="risk-cell">Expert consensus ranks Isomorphic #1 for small molecules. DeepMind talent + Alphabet compute are durable moats. Only 15% of pharma has AI in full rollout.</div></div>
        <div class="risk-row"><div class="risk-cell"><strong>Revenue Model Maturity</strong>Subscription revenue is early; pipeline economics years away</div><div class="risk-cell">Partnership milestones with Lilly/Novartis provide near-term revenue. De-risked Phase 3 assets valued at $3.4B — each successful program is transformative.</div></div>
      </div>
    </div>
  </div>

  <!-- STRIPES OVERVIEW -->
  <div class="content-panel" data-node="team">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:var(--accent)">Stripes Overview</span></div>
      <div class="label">Stripes Overview</div>
      <h2 class="sec-title">We help teams with amazing products<br>build categories that matter</h2>
      <p class="sec-sub">Founded in 2008 with a mission to invest in best-in-class technology and consumer products. Based in NYC, investing globally with $8B AUM.</p>

      <!-- Investment Timeline -->
      <h3 style="font-size:18px;font-family:var(--font-g);font-weight:700;margin:32px 0 16px">Key Portfolio Milestones</h3>
      <div class="timeline" id="investTimeline">
        <div class="timeline-item"><div class="tl-date">Series C Lead</div><h4>monday.com</h4><p>Brand marketing strategy, IPO preparation → NASDAQ: MNDY, <strong style="color:var(--accent)">$14.9B</strong> market cap</p></div>
        <div class="timeline-item"><div class="tl-date">First Institutional Investor</div><h4>On Running</h4><p>eCommerce optimization, strategic intros → NYSE: ONON, <strong style="color:var(--accent)">$19.5B</strong> market cap</p></div>
        <div class="timeline-item"><div class="tl-date">Led $225M Round</div><h4>A24</h4><p>Category-defining entertainment brand → Private valuation: <strong style="color:var(--accent)">$3.5B+</strong></p></div>
      </div>

      <div class="partner-grid">
        <div class="p-card" onclick="toggleExpand(this)">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#6161FF"><img src="https://www.google.com/s2/favicons?domain=monday.com&sz=128" alt="monday.com"></div><div class="name">monday.com</div></div>
          <div class="type">Led Series C → NASDAQ: MNDY</div>
          <div class="desc">Brand marketing strategy, financial reporting best practices, IPO preparation. Current market cap: <strong style="color:var(--text)">$14.9B</strong></div>
          <div class="p-extra">Stripes helped monday.com refine their brand positioning and prepared the company for its successful IPO. Our Scale Team provided direct support on financial reporting and investor relations.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#000;border:1px solid #444"><img src="https://www.google.com/s2/favicons?domain=on-running.com&sz=128" alt="On Running"></div><div class="name">On Running</div></div>
          <div class="type">First Institutional Investor → NYSE: ONON</div>
          <div class="desc">eCommerce optimization, strategic intros (Equinox, Nordstrom), Hillhouse Capital intro for Asia. Current market cap: <strong style="color:var(--text)">$19.5B</strong></div>
          <div class="p-extra">As the first institutional investor, Stripes provided foundational support including eCommerce strategy, key retail partnerships, and introductions to expand into Asian markets.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#000;border:1px solid #444"><img src="https://www.google.com/s2/favicons?domain=a24films.com&sz=128" alt="A24"></div><div class="name">A24</div></div>
          <div class="type">Led $225M Round</div>
          <div class="desc">Category-defining entertainment brand. Private valuation: <strong style="color:var(--text)">$3.5B+</strong></div>
          <div class="p-extra">A24 exemplifies our philosophy of investing in category-defining companies with unique brand identity and deep cultural resonance.</div>
        </div>
      </div>
    </div>
  </div>

  <!-- SCALE TEAM -->
  <div class="content-panel" data-node="scaleteam">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#24D164,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#24D164">Scale Team</span></div>
      <div class="label">Scale Team</div>
      <h2 class="sec-title">Dedicated operating resources<br>to help Isomorphic <span class="gradient-text">scale faster</span></h2>
      <p class="sec-sub">Stripes' in-house Scale Team provides hands-on support across every critical function — not just capital, but execution firepower embedded alongside your team.</p>

      <div style="display:grid;grid-template-columns:repeat(3,1fr);gap:16px;margin-top:32px">
        <div style="background:rgba(99,91,255,.06);border-radius:14px;padding:20px;border:1px solid rgba(99,91,255,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--accent);margin-bottom:8px">Talent</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Executive search, org design, compensation benchmarking, employer branding</p>
        </div>
        <div style="background:rgba(36,209,100,.06);border-radius:14px;padding:20px;border:1px solid rgba(36,209,100,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--green);margin-bottom:8px">Marketing & Brand</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Brand positioning, content strategy, demand generation, event marketing</p>
        </div>
        <div style="background:rgba(255,122,0,.06);border-radius:14px;padding:20px;border:1px solid rgba(255,122,0,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--orange);margin-bottom:8px">Finance & Legal</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">FP&A setup, audit readiness, legal counsel, entity structuring, tax strategy</p>
        </div>
        <div style="background:rgba(128,233,255,.06);border-radius:14px;padding:20px;border:1px solid rgba(128,233,255,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:#0CB7D6;margin-bottom:8px">Data & Analytics</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Data infrastructure, KPI dashboards, customer analytics, pricing optimization</p>
        </div>
        <div style="background:rgba(255,92,170,.06);border-radius:14px;padding:20px;border:1px solid rgba(255,92,170,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:#FF5CAA;margin-bottom:8px">Growth & Sales</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">GTM strategy, enterprise sales playbooks, pipeline management, partnership sourcing</p>
        </div>
        <div style="background:rgba(200,169,90,.06);border-radius:14px;padding:20px;border:1px solid rgba(200,169,90,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--gold);margin-bottom:8px">Operations</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Procurement, vendor management, international expansion, systems & process design</p>
        </div>
      </div>

      <h3 style="font-size:18px;font-family:var(--font-g);font-weight:700;margin:40px 0 16px">Immediate Value-Add for Isomorphic Labs</h3>
      <div style="display:grid;grid-template-columns:1fr 1fr;gap:14px">
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid var(--accent)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Enterprise GTM Buildout</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Help design and staff the enterprise sales motion for pharma partnerships — including territory planning, pricing strategy, and customer success frameworks</p>
        </div>
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid var(--green)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Executive Talent Pipeline</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Source and recruit senior commercial leaders with pharma/biotech experience — CRO, VP Sales, Head of Partnerships — through our proprietary network</p>
        </div>
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid var(--orange)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Pharma Customer Intros</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Leverage advisory council relationships to open doors at top 20 pharma — warm intros to R&D decision-makers and Chief Digital Officers</p>
        </div>
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid #FF5CAA">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Brand & Thought Leadership</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Position Isomorphic as the category leader in AI drug discovery — conference strategy, media relations, case study development, and analyst engagement</p>
        </div>
      </div>
    </div>
  </div>

  <!-- HEALTHCARE EXPERTISE -->
  <div class="content-panel" data-node="healthcare">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF6B9D,#FF5CAA)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#FF6B9D">Healthcare Expertise</span></div>
      <div class="label">Healthcare Expertise</div>
      <h2 class="sec-title">Deep experience in<br><span class="gradient-text">healthcare & life sciences</span></h2>
      <p class="sec-sub">Healthcare is a core vertical for Stripes. We've built category leaders across pharma services, health tech, clinical analytics, and digital health — giving us pattern recognition directly relevant to Isomorphic.</p>

      <div class="partner-grid" style="grid-template-columns:1fr;gap:16px;margin-top:24px">
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#1D71B8"><img src="https://www.google.com/s2/favicons?domain=flatiron.com&sz=128" alt="Flatiron Health"></div><div class="name">Flatiron Health</div></div>
          <div class="type">Oncology SaaS & Real-World Evidence • Acquired by Roche for $2.1B</div>
          <div class="desc">Placed CFO, Chief People Officer, IPO Controller; intros into RCM and RWE businesses. <strong style="color:var(--green)">$29M → $90M ARR (57% CAGR)</strong></div>
          <div class="p-extra">Stripes placed three C-suite executives and provided strategic introductions that helped Flatiron scale its real-world evidence platform, ultimately leading to Roche's $2.1B acquisition. Directly relevant to Isomorphic as a pharma platform company that scaled into enterprise deals with large pharma.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#FF6B9D"><img src="https://www.google.com/s2/favicons?domain=pomelocare.com&sz=128" alt="Pomelo Care"></div><div class="name">Pomelo Care</div></div>
          <div class="type">Virtual Maternal Care Platform</div>
          <div class="desc">Advised on performance marketing, strategy to expand to Medicare/Commercial. <strong style="color:var(--green)">$11M → $66M revenue run rate (230% CAGR)</strong></div>
          <div class="p-extra">Our Scale Team connected Pomelo with payer network contacts and helped design their expansion strategy into Medicare and commercial insurance markets.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#6C63FF"><img src="https://www.google.com/s2/favicons?domain=equip.health&sz=128" alt="Equip"></div><div class="name">Equip</div></div>
          <div class="type">Virtual Eating Disorder Treatment</div>
          <div class="desc">Evidence-based, family-centered eating disorder treatment delivered via telehealth. Rapid scale through payer partnerships and clinical outcomes data.</div>
          <div class="p-extra">Equip demonstrates Stripes' ability to scale digital health platforms that require clinical rigor, payer contracting, and evidence-based validation — capabilities directly transferable to Isomorphic's pharma engagement model.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#2B7A78"><img src="https://www.google.com/s2/favicons?domain=boulder.care&sz=128" alt="Boulder Care"></div><div class="name">Boulder Care</div></div>
          <div class="type">Virtual Addiction Medicine</div>
          <div class="desc">Tech-enabled substance use disorder treatment platform. Scaled through Medicaid and commercial payer partnerships.</div>
          <div class="p-extra">Boulder's model of using technology to improve clinical outcomes in a highly regulated environment mirrors the challenges Isomorphic faces in gaining pharma trust and regulatory acceptance.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#E8475F"><img src="https://www.google.com/s2/favicons?domain=helloheart.com&sz=128" alt="Hello Heart"></div><div class="name">Hello Heart</div></div>
          <div class="type">Digital Cardiovascular Health</div>
          <div class="desc">AI-powered heart health platform with clinically validated outcomes. Deployed through employer and health plan channels.</div>
          <div class="p-extra">Hello Heart's combination of AI/ML-driven insights with clinical validation is a strong parallel to Isomorphic's approach — both require rigorous evidence to win enterprise healthcare buyers.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#1A3C5E"><img src="https://www.google.com/s2/favicons?domain=chapter.com&sz=128" alt="Chapter"></div><div class="name">Chapter</div></div>
          <div class="type">Medicare Advisory Platform</div>
          <div class="desc">Tech-enabled Medicare advisory helping seniors navigate plan selection. Scaled through direct-to-consumer and B2B2C channels.</div>
          <div class="p-extra">Chapter shows Stripes' expertise in scaling healthcare platforms that require deep domain knowledge, regulatory navigation, and trust-building — all relevant to Isomorphic's pharma engagement.</div>
        </div>
      </div>

      <div style="background:rgba(255,107,157,.04);border-radius:12px;padding:16px 20px;margin-top:24px;border:1px solid rgba(255,107,157,.06)">
        <p style="font-size:12.5px;color:var(--text2);line-height:1.6;margin:0"><strong style="color:var(--text)">Pattern recognition:</strong> Across these investments we've learned how to sell complex technology platforms into pharma R&D organizations — long sales cycles, multi-stakeholder buying committees, compliance requirements, and the importance of clinical validation.</p>
      </div>
    </div>
  </div>

  <!-- OPERATING PARTNERS -->
  <div class="content-panel" data-node="ops">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#80E9FF">Operating Partners</span></div>
      <div class="label">Operating Partners</div>
      <h2 class="sec-title">Relevant expertise to<br>help Isomorphic <span class="gradient-text">scale</span></h2>
      <p class="sec-sub">Our Operating Partners are former C-suite executives who work hands-on with portfolio companies — not just advisory, but embedded operational support.</p>

      <div class="team-grid" style="grid-template-columns:repeat(2,1fr);gap:18px;margin-top:28px">
        <div class="team-card" style="padding:22px">
          <h4 style="margin-bottom:2px">Paul Melchiorre</h4>
          <div class="role" style="color:var(--accent);margin-bottom:10px">Former CRO, Anaplan</div>
          <p style="font-size:13px;line-height:1.5;margin-bottom:10px">20+ years leading enterprise sales at SAP, Ariba, and Anaplan. Scaled Anaplan from $50M to $300M+ ARR.</p>
          <div style="background:rgba(99,91,255,.06);border-radius:8px;padding:10px 14px;font-size:12px;color:var(--accent)"><strong>Isomorphic relevance:</strong> Enterprise sales motion design for pharma — territory planning, pricing models, and building repeatable large-deal playbooks</div>
        </div>
        <div class="team-card" style="padding:22px">
          <h4 style="margin-bottom:2px">Scott Aronson</h4>
          <div class="role" style="color:var(--accent);margin-bottom:10px">Former COO, Cloudera</div>
          <p style="font-size:13px;line-height:1.5;margin-bottom:10px">Scaled Cloudera's platform business through IPO. Deep experience in enterprise data infrastructure and platform GTM.</p>
          <div style="background:rgba(99,91,255,.06);border-radius:8px;padding:10px 14px;font-size:12px;color:var(--accent)"><strong>Isomorphic relevance:</strong> Platform-as-a-service GTM strategy — transitioning from custom engagements to scalable, repeatable platform offerings</div>
        </div>
        <div class="team-card" style="padding:22px">
          <h4 style="margin-bottom:2px">Jindra Zitek</h4>
          <div class="role" style="color:var(--accent);margin-bottom:10px">Former CIO, Chobani</div>
          <p style="font-size:13px;line-height:1.5;margin-bottom:10px">Led digital transformation and enterprise data strategy across global operations. Deep expertise in data infrastructure.</p>
          <div style="background:rgba(99,91,255,.06);border-radius:8px;padding:10px 14px;font-size:12px;color:var(--accent)"><strong>Isomorphic relevance:</strong> Data infrastructure at scale — critical for managing pharma-grade datasets, compliance, and secure compute environments</div>
        </div>
        <div class="team-card" style="padding:22px">
          <h4 style="margin-bottom:2px">Sharon Rothstein</h4>
          <div class="role" style="color:var(--accent);margin-bottom:10px">Former Global CMO, Starbucks</div>
          <p style="font-size:13px;line-height:1.5;margin-bottom:10px">Built Starbucks into a global brand icon. Expert in category creation and premium brand positioning.</p>
          <div style="background:rgba(99,91,255,.06);border-radius:8px;padding:10px 14px;font-size:12px;color:var(--accent)"><strong>Isomorphic relevance:</strong> Category leadership positioning — establishing Isomorphic as the definitive AI drug discovery platform in a crowded landscape</div>
        </div>
        <div class="team-card" style="padding:22px">
          <h4 style="margin-bottom:2px">Mike Vaughan</h4>
          <div class="role" style="color:var(--accent);margin-bottom:10px">Former COO, Venmo</div>
          <p style="font-size:13px;line-height:1.5;margin-bottom:10px">Scaled Venmo's operations through hypergrowth and PayPal integration. Expert in organizational design and process.</p>
          <div style="background:rgba(99,91,255,.06);border-radius:8px;padding:10px 14px;font-size:12px;color:var(--accent)"><strong>Isomorphic relevance:</strong> Operational scaling — building the systems and processes to support rapid headcount and revenue growth</div>
        </div>
        <div class="team-card" style="padding:22px">
          <h4 style="margin-bottom:2px">Julie Herendeen</h4>
          <div class="role" style="color:var(--accent);margin-bottom:10px">Former CMO, Dropbox</div>
          <p style="font-size:13px;line-height:1.5;margin-bottom:10px">Led Dropbox's growth marketing through IPO. Deep expertise in product-led growth and enterprise expansion.</p>
          <div style="background:rgba(99,91,255,.06);border-radius:8px;padding:10px 14px;font-size:12px;color:var(--accent)"><strong>Isomorphic relevance:</strong> Growth marketing playbook — driving awareness and pipeline within the pharma/biotech buyer community</div>
        </div>
      </div>
    </div>
  </div>

  <!-- ADVISORY COUNCILS -->
  <div class="content-panel" data-node="councils">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF5CAA,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#FF5CAA">Advisory Councils</span></div>
      <div class="label">Advisory Network</div>
      <h2 class="sec-title">Unlock access to our<br><span class="gradient-text">advisory councils</span></h2>
      <p class="sec-sub">Five specialized councils of senior executives from the world's leading companies. Direct access to decision-makers who can open doors, validate strategy, and accelerate Isomorphic's commercial traction.</p>

      <div style="display:grid;grid-template-columns:1fr 1fr;gap:16px;margin-top:28px">
        <div style="background:rgba(99,91,255,.05);border-radius:14px;padding:20px;border:1px solid rgba(99,91,255,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:15px;margin-bottom:12px;color:var(--accent)">CIO Council</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0 0 12px">Technology leaders who evaluate and deploy enterprise AI platforms</p>
          <div class="logo-row" style="gap:12px;flex-wrap:wrap">
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#D51E27;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=jnj.com&sz=128" alt="J&J"></div><div class="lr-name" style="font-size:11px">J&J</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#0078D4;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=microsoft.com&sz=128" alt="Microsoft"></div><div class="lr-name" style="font-size:11px">Microsoft</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#FF9900;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=amazon.com&sz=128" alt="Amazon"></div><div class="lr-name" style="font-size:11px">Amazon</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#003087;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=paypal.com&sz=128" alt="PayPal"></div><div class="lr-name" style="font-size:11px">PayPal</div></div>
          </div>
        </div>
        <div style="background:rgba(255,107,157,.05);border-radius:14px;padding:20px;border:1px solid rgba(255,107,157,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:15px;margin-bottom:12px;color:#FF6B9D">Healthcare Council</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0 0 12px">Healthcare executives who understand pharma procurement and R&D workflows</p>
          <div class="logo-row" style="gap:12px;flex-wrap:wrap">
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#D51E27;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=jnj.com&sz=128" alt="J&J"></div><div class="lr-name" style="font-size:11px">J&J</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#002855;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=unitedhealthgroup.com&sz=128" alt="UHG"></div><div class="lr-name" style="font-size:11px">UnitedHealth</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#00447C;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=cigna.com&sz=128" alt="Cigna"></div><div class="lr-name" style="font-size:11px">Cigna</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#563d7c;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=providence.org&sz=128" alt="Providence"></div><div class="lr-name" style="font-size:11px">Providence</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#00B140;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=oscar.com&sz=128" alt="Oscar"></div><div class="lr-name" style="font-size:11px">Oscar Health</div></div>
          </div>
        </div>
        <div style="background:rgba(36,209,100,.05);border-radius:14px;padding:20px;border:1px solid rgba(36,209,100,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:15px;margin-bottom:12px;color:var(--green)">CFO Council</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0 0 12px">Finance leaders who influence budget allocation and vendor procurement</p>
          <div class="logo-row" style="gap:12px;flex-wrap:wrap">
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#ED1C24;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=coca-colacompany.com&sz=128" alt="Coca-Cola"></div><div class="lr-name" style="font-size:11px">Coca-Cola</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#004B87;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=united.com&sz=128" alt="United Airlines"></div><div class="lr-name" style="font-size:11px">United Airlines</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#CB1F47;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=aig.com&sz=128" alt="AIG"></div><div class="lr-name" style="font-size:11px">AIG</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#1877F2;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=fanatics.com&sz=128" alt="Fanatics"></div><div class="lr-name" style="font-size:11px">Fanatics</div></div>
          </div>
        </div>
        <div style="background:rgba(255,122,0,.05);border-radius:14px;padding:20px;border:1px solid rgba(255,122,0,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:15px;margin-bottom:12px;color:var(--orange)">CMO Council</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0 0 12px">Marketing leaders who can advise on brand strategy and market positioning</p>
          <div class="logo-row" style="gap:12px;flex-wrap:wrap">
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#000;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=sephora.com&sz=128" alt="Sephora"></div><div class="lr-name" style="font-size:11px">Sephora</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#ED6C2D;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=toasttab.com&sz=128" alt="Toast"></div><div class="lr-name" style="font-size:11px">Toast</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#E03C31;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=ulta.com&sz=128" alt="Ulta"></div><div class="lr-name" style="font-size:11px">Ulta</div></div>
            <div class="lr-item"><div class="lr-icon no-pad" style="background:#CF202F;width:24px;height:24px;border-radius:5px"><img src="https://www.google.com/s2/favicons?domain=hasbro.com&sz=128" alt="Hasbro"></div><div class="lr-name" style="font-size:11px">Hasbro</div></div>
          </div>
        </div>
      </div>

      <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:18px 22px;margin-top:24px;border:1px solid rgba(99,91,255,.06)">
        <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:8px">How Isomorphic Benefits</div>
        <p style="font-size:12.5px;color:var(--text2);line-height:1.6;margin:0">Our Healthcare Council and CIO Council members include R&D and technology decision-makers at major pharma companies. These relationships provide warm introductions to prospective customers, help validate product-market fit, and give Isomorphic a direct line to the buyers who control AI procurement budgets.</p>
      </div>
    </div>
  </div>

  <!-- THANK YOU / CTA -->
  <div class="content-panel" data-node="end">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:var(--accent)">Thank You</span></div>
      <div class="cta-content">
        <div class="hero-eyebrow" style="justify-content:center;margin-bottom:24px">
          <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" class="brand-logo-lg" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em>///\\ STRIPES</span>'">
          <span class="x-mark">×</span>
          <span class="iso-logo" style="height:28px">
            <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
            <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:3px"></span>
          </span>
        </div>
        <h2>Thank You</h2>
        <p>We believe Isomorphic Labs can revolutionize drug discovery. Let's build the future of medicine together.</p>
      </div>
      <div class="cta-footer">
        <span>Stripes × Isomorphic Labs • February 2026</span>
        <span>Confidential — For Discussion Purposes Only</span>
      </div>
    </div>
  </div>

</div>

<!-- ══ CDN DEPENDENCIES ══ -->
<script src="https://cdn.jsdelivr.net/npm/gsap@3.12.7/dist/gsap.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/lottie-web/5.12.2/lottie.min.js"></script>

<script>
// ═══════════════════════════
// NODE DATA (for cluster nav)
// ═══════════════════════════
const nodeData = [
  { id:'hero', label:'Cover', cluster:'Introduction', color:'#635BFF' },
  { id:'investments', label:'Recent Investments', cluster:'Introduction', color:'#80E9FF' },
  { id:'rdcrisis', label:'R&D Productivity Crisis', cluster:'Industry Landscape', color:'#E85D75' },
  { id:'trialheadwinds', label:'Clinical Trial Headwinds', cluster:'Industry Landscape', color:'#FF7A00' },
  { id:'aivalue', label:'AI Across Pharma', cluster:'Industry Landscape', color:'#635BFF' },
  { id:'rdparadigms', label:'R&D Paradigms', cluster:'Industry Landscape', color:'#80E9FF' },
  { id:'inflection', label:'Pharma Inflection', cluster:'Our Perspective', color:'#FF4D6D' },
  { id:'diligence', label:'Market Diligence', cluster:'Our Perspective', color:'#24D164' },
  { id:'thesis', label:'Investment Thesis', cluster:'Our Perspective', color:'#635BFF' },
  { id:'uvp', label:'Unique Value Prop', cluster:'Our Perspective', color:'#80E9FF' },
  { id:'validation', label:'Customer Validation', cluster:'Our Perspective', color:'#C8A95A' },
  { id:'competitive', label:'Competitive Landscape', cluster:'Our Perspective', color:'#FF5CAA' },
  { id:'growth', label:'Growth Vectors', cluster:'Our Perspective', color:'#24D164' },
  { id:'risks', label:'Risks & Mitigants', cluster:'Our Perspective', color:'#FF7A00' },
  { id:'team', label:'Stripes Overview', cluster:'Our Team', color:'#635BFF' },
  { id:'scaleteam', label:'Scale Team', cluster:'Our Team', color:'#24D164' },
  { id:'healthcare', label:'Healthcare Expertise', cluster:'Our Team', color:'#FF6B9D' },
  { id:'ops', label:'Operating Partners', cluster:'Our Team', color:'#80E9FF' },
  { id:'councils', label:'Advisory Councils', cluster:'Our Team', color:'#FF5CAA' },
  { id:'end', label:'Thank You', cluster:'Our Team', color:'#635BFF' },
];

// ═══════════════════════════
// STATE
// ═══════════════════════════
let appState = 'home'; // 'home' | 'content'
let activeNodeId = null;
const isMobile = window.matchMedia('(max-width:768px)').matches || 'ontouchstart' in window;

// ═══════════════════════════
// DOM REFERENCES
// ═══════════════════════════
const sceneContainer = document.getElementById('scene-container');
const deckNav = document.getElementById('deckNav');
const backBtn = document.getElementById('backBtn');
const clusterNav = document.getElementById('clusterNav');
const brandOverlay = document.getElementById('brandOverlay');

// ═══════════════════════════
// NAVIGATION OVERLAY LOGIC
// ═══════════════════════════
window.toggleNavSection = function(titleEl) {
  const section = titleEl.closest('.nav-section');
  // Accordion: close all others, toggle clicked — works in both home and sidebar mode
  const isExpanded = section.classList.contains('expanded');
  deckNav.querySelectorAll('.nav-section.expanded').forEach(s => s.classList.remove('expanded'));
  if (!isExpanded) section.classList.add('expanded');
  // In sidebar mode, also navigate to the first item of the opened section
  if (!isExpanded && deckNav.classList.contains('sidebar')) {
    const firstItem = section.querySelector('.nav-item');
    if (firstItem && firstItem.dataset.target) {
      switchPanel(firstItem.dataset.target);
    }
  }
};

// Nav item click → open content panel
document.querySelectorAll('.nav-item').forEach(btn => {
  btn.addEventListener('click', () => {
    const target = btn.dataset.target;
    if (target) openPanel(target);
  });
});

// ═══════════════════════════
// OPEN PANEL
// ═══════════════════════════
function openPanel(nodeId) {
  // If already viewing a panel, just switch
  if (appState === 'content') {
    switchPanel(nodeId);
    return;
  }

  appState = 'content';
  activeNodeId = nodeId;

  // Subtle video overlay shift
  sceneContainer.classList.add('panel-open');

  // Slide nav to sidebar position
  deckNav.classList.add('sidebar');

  // Show back button
  backBtn.classList.add('visible');

  // Build cluster nav
  buildClusterNav(nodeId);

  // Show the panel
  showPanel(nodeId);
}

// ═══════════════════════════
// CLOSE PANEL (back to home)
// ═══════════════════════════
window.closePanel = function() {
  if (appState !== 'content') return;

  hidePanel(activeNodeId);
  appState = 'home';
  activeNodeId = null;

  // Restore video overlay
  sceneContainer.classList.remove('panel-open');

  // Return nav to center
  deckNav.classList.remove('sidebar');

  // Hide back button & cluster nav
  backBtn.classList.remove('visible');
  clusterNav.classList.remove('visible');
  clusterNav.innerHTML = '';
};

// ═══════════════════════════
// CONTENT PANEL SHOW/HIDE
// ═══════════════════════════
function showPanel(nodeId) {
  const panel = document.querySelector(`.content-panel[data-node="${nodeId}"]`);
  if (!panel) return;
  panel.scrollTop = 0;
  panel.classList.add('active');

  // Stagger entrance of panel inner children
  const children = panel.querySelectorAll('.panel-inner > *');
  children.forEach((child, i) => {
    child.style.opacity = '0';
    child.style.transform = 'translateY(16px)';
    setTimeout(() => {
      child.style.transition = 'opacity .45s cubic-bezier(.22,1,.36,1), transform .45s cubic-bezier(.22,1,.36,1)';
      child.style.opacity = '1';
      child.style.transform = 'translateY(0)';
    }, 100 + i * 60);
  });

  setTimeout(() => animateCounters(panel), 200);
  setTimeout(() => animateMiniBars(panel), 300);
  setTimeout(() => animateTimeline(panel), 400);
}

function hidePanel(nodeId) {
  const panel = document.querySelector(`.content-panel[data-node="${nodeId}"]`);
  if (!panel) return;
  panel.classList.remove('active');
  // Reset child styles for next open
  panel.querySelectorAll('.panel-inner > *').forEach(child => {
    child.style.opacity = '';
    child.style.transform = '';
    child.style.transition = '';
  });
}

// ═══════════════════════════
// SWITCH PANEL (within content view)
// ═══════════════════════════
function switchPanel(newNodeId) {
  if (newNodeId === activeNodeId) return;

  hidePanel(activeNodeId);
  activeNodeId = newNodeId;
  showPanel(newNodeId);
  buildClusterNav(newNodeId);
}

// ═══════════════════════════
// CLUSTER NAV (right side dots)
// ═══════════════════════════
function buildClusterNav(activeId) {
  const activeNode = nodeData.find(n => n.id === activeId);
  if (!activeNode) return;

  const cluster = activeNode.cluster;
  const clusterNodes = nodeData.filter(n => n.cluster === cluster);
  clusterNav.innerHTML = '';

  clusterNodes.forEach(n => {
    const dot = document.createElement('div');
    dot.className = 'cluster-nav-dot' + (n.id === activeId ? ' active' : '');
    dot.style.background = n.color;
    dot.style.position = 'relative';
    dot.innerHTML = `<div class="cn-tip">${n.label}</div>`;
    dot.onclick = () => {
      if (n.id !== activeNodeId) {
        hidePanel(activeNodeId);
        activeNodeId = n.id;
        showPanel(n.id);
        buildClusterNav(n.id);
      }
    };
    clusterNav.appendChild(dot);
  });

  clusterNav.classList.add('visible');
}

// ═══════════════════════════
// ANIMATED COUNTERS
// ═══════════════════════════
function animateCounters(panel) {
  const counters = panel.querySelectorAll('[data-count]');
  counters.forEach(el => {
    const target = parseFloat(el.dataset.count);
    const prefix = el.dataset.prefix || '';
    const suffix = el.dataset.suffix || '';
    const decimals = parseInt(el.dataset.decimals || '0');
    const obj = { val: 0 };
    gsap.to(obj, {
      val: target,
      duration: 1.5,
      ease: 'power2.out',
      onUpdate: () => {
        el.textContent = prefix + obj.val.toFixed(decimals) + suffix;
      }
    });
  });
}

// ═══════════════════════════
// MINI BAR CHARTS
// ═══════════════════════════
function animateMiniBars(panel) {
  const bars = panel.querySelectorAll('.mini-bar-fill');
  bars.forEach(bar => {
    const width = bar.dataset.width || '0%';
    gsap.to(bar, { width: width, duration: 1.2, ease: 'power2.out', delay: 0.3 });
  });
}

// ═══════════════════════════
// TIMELINE ANIMATION
// ═══════════════════════════
function animateTimeline(panel) {
  const items = panel.querySelectorAll('.timeline-item');
  items.forEach((item, i) => {
    setTimeout(() => item.classList.add('tl-visible'), 200 + i * 200);
  });
}

// ═══════════════════════════
// EXPANDABLE CARDS
// ═══════════════════════════
window.toggleExpand = function(el) {
  const isExpanded = el.classList.contains('expanded');
  const parent = el.parentElement;
  if (parent) {
    parent.querySelectorAll('.expanded').forEach(sib => {
      if (sib !== el) sib.classList.remove('expanded');
    });
  }
  el.classList.toggle('expanded', !isExpanded);
};

// ═══════════════════════════
// KEYBOARD NAV
// ═══════════════════════════
window.addEventListener('keydown', (e) => {
  if (e.key === 'Escape' && appState === 'content') {
    closePanel();
  }
});

// ═══════════════════════════
// VIDEO BACKGROUND SETUP
// ═══════════════════════════
const bgVideo = document.getElementById('bgVideo');
bgVideo.src = 'home_hero.webm';
bgVideo.load();
bgVideo.play().catch(() => {});

// Fallback: if local fails, try remote
bgVideo.addEventListener('error', function fallback() {
  bgVideo.removeEventListener('error', fallback);
  bgVideo.src = 'https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/videos/home/home_hero.webm';
  bgVideo.load();
  bgVideo.play().catch(() => {});
}, true);

// ═══════════════════════════
// CLICK OUTSIDE TO CLOSE
// ═══════════════════════════
document.getElementById('video-overlay').addEventListener('click', () => {
  if (appState === 'content') closePanel();
});

// ═══════════════════════════
// LOADING SCREEN
// ═══════════════════════════
const loaderText = document.getElementById('loaderText');
const loadMessages = ['Folding protein structure...', 'Loading visualization...', 'Ready'];
let msgIdx = 0;
const msgInterval = setInterval(() => {
  msgIdx++;
  if (msgIdx < loadMessages.length) {
    loaderText.textContent = loadMessages[msgIdx];
  } else {
    clearInterval(msgInterval);
  }
}, 800);

// Dismiss loader when video is ready (or after 4s fallback)
bgVideo.addEventListener('canplaythrough', () => {
  setTimeout(() => {
    document.getElementById('loader').classList.add('done');
    bgVideo.play().catch(() => {});
  }, 800);
}, { once: true });

setTimeout(() => {
  document.getElementById('loader').classList.add('done');
}, 4000);

// ═══════════════════════════
// ANIMATED ISOMORPHIC LOGO (Lottie)
// ═══════════════════════════
const ISO_LOTTIE_URL = 'https://cdn.prod.website-files.com/63692b9f2544be26f383691c/638dc2f2c52f540707527ef9_ISO_logo.json';
const isoLottieInstances = [];

document.querySelectorAll('[data-iso-lottie]').forEach(container => {
  const anim = lottie.loadAnimation({
    container: container,
    renderer: 'svg',
    loop: false,
    autoplay: false,
    path: ISO_LOTTIE_URL
  });
  isoLottieInstances.push({ anim, container });

  // Play animation on hover (replay from start)
  const hoverTarget = container.closest('.brand-overlay') || container.closest('.hero-eyebrow') || container;
  hoverTarget.addEventListener('mouseenter', () => {
    anim.goToAndPlay(0, true);
  });
});

// Play all on page load after loader finishes
setTimeout(() => {
  isoLottieInstances.forEach(({ anim }) => anim.goToAndPlay(0, true));
}, 2400);

// Replay brand overlay logo when transitioning between home/content
const origOpenPanel = openPanel;
openPanel = function(nodeId) {
  origOpenPanel(nodeId);
  isoLottieInstances.forEach(({ anim }) => anim.goToAndPlay(0, true));
};
const origClosePanel = closePanel;
closePanel = function() {
  origClosePanel();
  isoLottieInstances.forEach(({ anim }) => anim.goToAndPlay(0, true));
};
</script>
</body>
</html>
